





# 2024 Annual Report





# Contents

---

Company Information	3
About ClearVue Technologies	4
Our Business Strategy	5
Drivers for Growth	7
FY24 Highlights	9
Chairman's Letter to Shareholders	11
CEO's Letter to Shareholders	12
Director's Report	13
Auditor's Independence Declaration	31
Consolidated Statement of Profit or Loss and Other Comprehensive Income	32
Consolidated Statement of Financial Position	33
Consolidated Statement of Changes in Equity	34
Consolidated Statement of Cash Flows	35
Notes to the Consolidated Financial Statements	36
Consolidated Entity Disclosure Statement	63
Director's Declaration	64
Independent Auditor's Report	65
ASX Additional Information	69

# Company Information

## CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES

ABN 45 071 397 487

### DIRECTORS

Mr Victor Rosenberg, Non-Executive Chairman

Mr Jamie Lyford, Executive Director

Mr Gerd Hoenicke, Non-Executive Director

Mr Charles Mowrey, Executive Director

### COMPANY SECRETARY

Mr Harry Miller

Mr Brett Tucker

### REGISTERED OFFICE

Suite 9 / 567 Newcastle Street  
West Perth  
WA 6005

### PRINCIPAL BANKERS

National Australia Bank Limited  
Level 12, 100 St Georges Terrace  
Perth WA 6000

### AUDITORS

Grant Thornton Audit Pty Ltd  
Level 43, Central Park  
152-158 St Georges Terrace  
Perth WA 6000

### SOLICITORS

Steinepreis Paganin  
16 Milligan Street  
Perth WA 6000

### SHARE REGISTRY

Automic Group  
Level 5, 191 St George Terrace  
Perth WA 6000

### STOCK EXCHANGE LISTING

Shares are listed on the Australian Securities Exchange  
(ASX code: CPV)



# About ClearVue Technologies

ClearVue Technologies Ltd (“ClearVue” or the “Company”) is a global technology company, headquartered in Australia and specialising in the integration of advanced solar technology within building surfaces. ClearVue’s patented solar technology enhances the sustainability and energy efficiency of both new and existing buildings by generating energy from nearly all surfaces, not just the roof.

At the heart of ClearVue’s innovation is its proprietary solar glass technology, which enables energy generation from clear glass windows. ClearVue offers the only completely transparent, large-format solar glass suitable for building construction. This product not only meets architectural aesthetic standards but also achieves high energy efficiency for building owners. ClearVue solar glass can be utilised in windows, skylights, greenhouses, and facades, providing energy to power autonomous features or to feed into a grid or battery storage.


In combination with a range of complementary Building Integrated Photovoltaic (BIPV) products, ClearVue can create a building envelope where the entire surface area generates electricity. This addresses one of the most significant economic challenges since the Industrial Revolution: the decarbonisation of the global economy.

Our ability to deliver practical, actionable, and quantifiable net-zero or near-net-zero energy solutions for the built environment positions ClearVue to provide meaningful environmental, social, and shareholder benefits over the medium to long term.

Supporting our technology portfolio, the Company holds an extensive array of global patents, designs, trademarks, and trade secret protections. Additionally, ClearVue has undergone rigorous global testing to ensure compliance with the relevant standards for our key target markets in Europe, the United States, and the Middle East.

Since listed on the Australian Stock Exchange (“ASX”) in May 2018, ClearVue’s geographic footprint now extends from Australia to Europe and the United States. Through our license partners, our product footprint is increasingly global.

ClearVue is currently executing its commercialisation plan. The Company is guided by a board with extensive industry experience, complemented by an equally experienced executive team, to drive significant outcomes for our customers and shareholders.



*We generate energy from  
nearly all façade surfaces*



# Our Business Strategy

*We aspire to be the product of choice for the global built environment as the sector adopts net zero building standards.*

*Our strategy to achieve this aspiration includes:*

1

GLOBAL SALES  
THROUGH LICENSE  
PARTNERS

2

MULTIPLE REVENUE  
STREAMS LEVERAGED  
TO VOLUME GROWTH

3

CAPITAL LIGHT  
BUSINESS



The world is actively decarbonising. Building operations / energy usage represents 27% of global CO<sub>2</sub> emissions.



ClearVue's core technology allows a clear glass window to generate electricity, reducing carbon footprint and providing a path to net zero energy buildings.



The commercial Building Integrated Photovoltaic Market is projected to be \$88.4 billion by 2030, a CAGR of 20.5%

## REVENUE MODEL

=

ROYALTY ON SOLAR VISION  
GLASS

+

### SALE OF COMPONENTS

Nano particle interlayer  
Solar PV strips  
System components  
Solar Spandrel  
Solar Cladding

+

LICENCE FEE /  
RENEWAL FEE

## KEY PARTNERSHIPS: GLASS MANUFACTURERS LICENSEES

- The licensee model allows ClearVue to:
  - Access existing production capabilities
  - Leverage existing sales channels and client relationships in key markets
  - Profitable expansion with light capital requirements
- Benefits for licensees
  - Expansion into new and fast-growing markets
  - Simple assembly process for seamless integration into existing glass fabrication lines
  - Flash testing machine for quality assurance is the only additional piece of equipment required
- Focus on large established glass manufacturers in key global markets.
  - License Fee Renewal charged every 3 or 5 years





# Drivers for Growth

GLOBAL TRENDS ARE SHAPING OUR WORLD, AND FUELING CLEARVUE'S COMMERCIALISATION

1

## THE WORLD IS ACTIVELY DECARBONISING



**90%**

of global GDP operates in a net zero environment

**8,000+**

Global companies and countries operate in a net zero environment

To achieve net zero goals, the operating carbon of the built environment needs to be considered as part of any viable solution to net zero aspirations.

2

## BEHAVIOURAL CHANGE WILL DRIVE POLITICAL AND COMMERCIAL AGENDA



**86%**

of global population want climate change action

**81%**

of executive incentives plans globally include ESG metrics

ClearVue provides governments and companies with a path to enact their ESG, climate change and meet consumer expectations.

3

## RENEWABLE ENERGY MARKET KEEPS BOOMING



**\$2 trillion**

Global spending on clean energy tech and infrastructure in 2024

The demand for innovative, practical solutions to achieve net zero obligations will attract the attention of capital markets.

4

## THE GROWTH IN URBAN AREAS



**241 billion m<sup>2</sup>**

of new floor space to add between 2020-2060

**+2 billion**

Urban population growth by 2050

The global population is moving into our cities creating unprecedented demand in the built environment. To meet this demand in a sustainably will be one of the challenges facing all governments around the world.

1. Source: <https://www.mckinsey.com/capabilities/sustainability/our-insights/an-affordable-reliable-competitive-path-to-net-zero>

2. Source: <https://www.ox.ac.uk/news/2024-06-20-80-percent-people-globally-want-stronger-climate-action-governments-according-new>  
<https://sustainabilitymag.com/esg/executive-pay-increasingly-linked-to-esg-metrics-and-climate>

3. Source: <https://www.iea.org/news/investment-in-clean-energy-this-year-is-set-to-be-twice-the-amount-going-to-fossil-fuels>

4. Source: <https://www.unfpa.org/urbanization#readmore-expand>  
<https://www.architecture2030.org/why-the-built-environment/>



# A Complete Solar Building Envelope Solution to Generate Electricity

## NET ZERO ENERGY BUILDINGS ARE NOW WITHIN REACH

### BENEFITS OF CLEARVUE SOLAR FAÇADE SOLUTION:

- A source of renewable energy on site – offsets up to 103% of the building's energy requirements<sup>1</sup>
- Accelerated carbon and financial payback – financial payback from 2-3 years<sup>1</sup>
- Turnkey solution for developers
- Provides a tangible pathway to enact ESG and renewable energy goals

#### SOLAR CLADDING



80+ colours, textures, and finishings for any look – stone, brick, glass, wood, metallic. Power output: up to 189 watts peak per m<sup>2</sup>.

#### SOLAR SPANDREL




All black units for maximum power generation – up to 200 watts peak per m<sup>2</sup>.

#### SOLAR VISION GLASS



Our core IP product – energy generating and energy-saving clear solar windows. Available in custom sizes (up to 3.5 x 2.1m), compatible with coatings and framing systems, this versatile product provides maximum light transparency, energy generation and reduced heat gain.

#### SOLAR BALUSTRADE



Semi-transparent photovoltaic glass to generate power from skylights and balustrades. Transparency and energy generation vary.

<sup>1</sup> Based on the Independent Energy Model Report by Footprint "ClearVue PV 40 Storey Archetype Office", April 2024, 60% Window-to-wall ratio data, [www.sa-footprint.com](http://www.sa-footprint.com)

# FY24 Highlights

*This year, the company made significant strides to commercialise the core IP product – clear solar glass, expand the product range to strengthen our offering and create additional revenue streams. We signed multiple license agreements and certified our products to enable sales.*

LEFT TO RIGHT: MAYOR MATT MAHAN, CHARLES MOWREY, VICTOR ROSENBERG, MARTIN DEIL




## ESTABLISHING NORTH AMERICAN OPERATIONS

- Chuck Mowrey, a board member since May 2023, started as CEO and President North America in May 2024
- Commercial launch in the United States: the first Greenhouse solar glass sale through System USA (AUD 252k), followed by a repeat order (AUD 175k).
- AIA24 participation brought ClearVue into the spotlight
- New offices in San Jose opened by Mayor Matt Mahan in June 2024
- Upgraded to OTCQX® Best Market listing

## COMMERCIAL LAUNCH IN AUSTRALIA

Kapitol Group incorporated ClearVue's Generation 2 solar windows into the façade of the CFMEU Training and Wellness Centre in Melbourne, the installation attracted national TV news coverage.







## Strategic Partnership

CLEARVUE SIGNS ALUTEC, QATAR'S LARGEST GLASS MANUFACTURER

## NEW LICENSEES

- 6 new licensees joined in 2024
- Strategic partnership with AluTec – August 2024
- 10+ licensees to sign up in 2025




## EXPANDING THE PRODUCT RANGE

Expansion of product range to offer a full solar building envelope solution and provide BIPV products for multiple applications:

- Solar cladding and spandrel
- Solar skylight and balustrade

## CERTIFICATIONS, TESTING AND R&D

- Energy efficiency testing at BCA in Singapore confirmed 22.8% reduction in cooling load and 7.5% overall energy savings after accounting for energy generation and 71% energy savings with the addition of the Solar Spandrel solution;
- The 'Zero Window'® prototype combining ClearVue's photovoltaic solar glazing and LuxWall's advanced vacuum-insulated glazing was demonstrated at AIA24.
- To enable sales, critical building product certifications achieved including EN13501-1 (Combustibility), IEC 61730 & IEC 61215 (Electrical safety), ASTM E 2190 (Sealed IGU performance).





# Chairman's Letter to Shareholders



Dear Shareholders,

On behalf of the Board, I am delighted to present ClearVue's Annual Report for the 2024 Financial Year.

ClearVue has had a remarkable twelve months establishing ourselves as a leader in smart building facade designs and a genuine contributor to the global net zero revolution in construction. Our unique technology will significantly enhance buildings with energy efficient, low emission technology that provides building owners around the world with tangible sustainability solutions.

FY2024 was pivotal for ClearVue as we firmly moved from an R&D company with unique core IP capable of generating the highest energy output from clear glass to a company with a comprehensive product line transforming entire building exteriors into individual renewable energy hubs as we begin to commercialise our technology

In parallel to developing our total building envelope solution, we laid the foundation for global expansion and scale by partnering with established and renowned façade manufacturers in key markets around the world. Pleasingly, we enjoyed first sales in the United States and Australia.

Our products are unique – there is simply no company in the world currently capable of producing floor-to-ceiling solar clear glass, or indeed any solar glass with the energy output of a ClearVue window. The energy efficiency and safety of our products have passed stringent international testing, and we've proven the mass manufacturing capability of our products.

We have an early mover advantage in a growing global market for clean energy products in the building and construction sector – a sector accounting for 40% of all global emissions – driven by mandates and evolving consumer sentiment. Governments around the world are increasingly looking for energy independence in the face of pandemics and conflicts that leave countries vulnerable to energy disruptions.

We welcomed Charles (Chuck) Mowrey as the new President and CEO of our North American operations. Chuck strengthens our executive team as we accelerate entry into North America as the most immediate and important strategic market for our technology given the significant market size and favourable regulatory environment.

On behalf of the Board, I thank the entire ClearVue team for their hard work, passion and commitment to our core mission as we contribute to a more sustainable future by enabling buildings to generate clean energy and reduce carbon footprints. Our achievements demonstrate the tangible difference our technology and commitment to innovation makes for our partners and first customers.

And lastly, thank you to our loyal shareholders. We appreciate your ongoing trust and investment in our company. We will continue to build on the solid progress we made this year on our growth trajectory, expand into new markets, and capitalise on the opportunities to deliver value.

Sincerely,

**Victor Rosenberg**  
Non-Executive Chairman

# CEO's Letter to Shareholders



My primary focus in my first full year as CEO was to prepare us for global launch in FY25. I'm pleased to report we have delivered against the roadmap we set out at the beginning of the financial year to ensure our products are market-ready, solidify our presence in our important North American market, and set ourselves up for rapid sales with established manufacturers around the world.

As we progressed along our path to commercialisation, we continued to innovate, building on our flagship clear solar glass with solar spandrel, solar cladding, and architectural BIPV (skylight and balustrading glass). Our full product suite, ClearVue Power Facade™ was unveiled at the AIA24 Conference on Architecture & Design in Washington DC to wide acclaim.

We can now generate power from the entire exterior surface of a building, increasing overall energy efficiency and significantly reducing the payback period. The ClearVue Power Facade™ is a 'plug and play' technology which can be sold as a whole building envelop solution for new buildings, or per product to retrofit existing buildings, setting us apart from competitors.

We have the necessary building blocks in place to scale. Our fully developed, certified product suite has proven mass-scale manufacturing capability and is compliant with international building codes and regulations across electrical, heat, fire safety and seal standards essential for our products to be included in design specifications.

While we pursue multiple markets around the world, our sights are set firmly on the US for full commercial launch. The US is our most important market given their openness to investing in new technology combined with a favourable regulatory environment incentivising companies to adopt clean energy.

We delivered our first sales in the US with a contract for solar greenhouses targeting the US protected cropping agriculture market opening an opportunity in global solar greenhouse glass currently worth US\$7.5 billion per year and growing.

Greenhouses are one of our key industry verticals as government's start to bolster their national food and energy security, mitigating against changing weather patterns, pandemics and conflict. Our technology not only provides a renewable energy solution for greenhouses, but indeed increases crop yield. We have since secured a repeat order, validating our technology and strengthening our relationship with a key player in the US greenhouse industry.

We commercially launched in Australia with a contract to install clear solar glass on a building façade. Importantly, this was the first building to have our products incorporated into the project design, showing the value architects are placing on smart building materials that improve energy efficiency.

A clear differentiator for ClearVue is our low operating cost business model, allowing us to scale quickly across multiple jurisdictions. Our business model is to provide our IP and components to a network of established licensee partners who manufacture and sell into their own markets, neutralising costly supply chains and shortening the sales cycle. We have been selective with the manufacturers we partner with, targeting those with established client bases and considerable networks beyond their direct country of origin.

Our sales will come through two parallel streams: via licensee partners and with our own direct sales to building owners, developers and architects. The projects we source directly, of which we currently have 50 opportunities in the pipeline, will be redirected to licensee partners to execute.

Our business model is driven by revenue derived from royalties from licensee partners, based on a per square metre of glass sold, a manufacturing margin on the selling of components to licensees, and renewal license fees from partners. Each license partner is contractually obligated to achieve a set sales target.

I'm proud to have been appointed CEO of ClearVue at an exciting phase in the Company's history. I look forward to continuing to lead the incredibly talented and dedicated ClearVue team as we cement our industry reputation and deliver our cutting-edge technology to fundamentally advance smart building design solutions.

And lastly, I would like to thank you, our loyal shareholders. We will continue to build on the solid progress we made this year continue our growth trajectory, expand into new markets, and capitalise on the opportunities to deliver value.

Sincerely,

**Martin Deil**  
Global CEO

## DIRECTOR'S REPORT

The directors are pleased to present the audited consolidated financial report of ClearVue Technologies Limited ABN 45 071 397 487 ("the Company") and its controlled entities ("the Group") for the year ended 30 June 2023.

The name of the directors in office at any time during or since the end of the year are:

- Mr Victor Rosenberg, Non-Executive Chairman
- Mr Jamie Lyford, Executive Director
- Mr Gerd Hoenicke, Non-Executive Director
- Mr Charles (Chuck) Mowrey, Executive Director

The qualifications, experience and special responsibilities of each director are as follows:



### VICTOR ROSENBERG

*Dip Pharm, MPS (SA)*

**Non-Executive Chairman & Founder**

**25 YRS GLASS INDUSTRY**

Mr Rosenberg is a serial entrepreneur, recognised globally for his contributions to the glass industry. Extensive business experience in senior management and sales over ~50 years.



### JAMIE LYFORD

*BCom, LLB, LLM(IP), PGradDip IT*

**Executive Director**

**28 YRS COMMERCIAL & IP LAW, COMMERCIALISATION**

Mr Lyford is an IP, technology, commercial and licensing lawyer with 28 years of experience at local, national and international law firms, BHP and global IT company ATOS.

Commercialisation specialist and operated Western Australian Government Innovation Centre.



### CHUCK MOWREY

*BSc Bus, MBA*

**Executive Director, President and CEO North America**

**40+ YRS COMMERCIAL GLASS AND GLAZING**

Mr Mowrey is the CEO of 8G Solutions, a leading U.S. contract glazier. He has more than 40 years of experience in the commercial glass and glazing industry gained over 5 decades. Mr Mowrey has led several companies to significant growth and onto an innovation path including Harmon Inc., Guardian Glass and others.





### GERD HOENICKE

*BEng Fac*

**Non-Executive Director**

**35+ YRS IN THE GLOBAL  
FAÇADE INDUSTRY**

Mr Hoenicke has worked as a CEO, a technical director, and a consultant for various internationally recognised façade companies (including Schneider, Seele and Schuco) and has an extensive portfolio of recognised façade projects. He currently runs his own consultancy business and works with architects and engineers on major US and European projects.



### MARTIN DEIL

*BSc*

**Global CEO**

**30 YEARS OF GLOBAL FAÇADE BUSINESS  
EXPERIENCE WITH EXECUTIVE POSITIONS**

Mr Deil brings a deep knowledge of the international façade and architectural envelopes business to ClearVue having spent the past 22 years in various senior management roles of increasing responsibility including as CEO, Deputy CEO and COO within the Permasteelisa Group in different locations globally. Mr Deil has a Bachelor of Science (Honours) Degree in Management and Systems from City University London.



### HARRY MILLER

*BCom, MPA*

**Company Secretary**

**8+ YEARS OF CORPORATE, COMPLIANCE  
AND ACCOUNTING EXPERIENCE**

Company Secretary to a number of ASX-listed and private organisations. Involved in various corporate transactions. Has previously worked with a leading global accounting firm based in Western Australia.

## REMUNERATION REPORT (AUDITED)

This report, which forms part of the Directors' report, outlines the remuneration arrangements in place for the key management personnel ("KMP") of ClearVue Technologies Limited for the financial year ended 30 June 2024. The information provided in this remuneration report has been prepared in accordance with the requirements of the Corporations Act 2001 and its Regulations and have been audited as required by Section 308(3C) of the Corporations Act 2001.

### KEY MANAGEMENT PERSONNEL

The KMP of the Company during or since the end of the financial year were as follows:

	PERIOD OF EMPLOYMENT
<b>DIRECTORS</b>	
Mr Victor Rosenberg, Non-Executive Chairman	Appointed 13 November 1995 to present
Mr Jamie Lyford, Executive Director	Appointed 10 February 2023 to present
Mr Gerd Hoenicke, Non-Executive Director	Appointed 1 May 2023 to present
Mr Charles Mowrey, Executive Director	Appointed 1 May 2023 to present
<b>KEY MANAGEMENT PERSONNEL</b>	
Martin Deil, Chief Executive Officer	Appointed 1 June 2023 to present
Mr Geoff Edwards, Chief Financial Officer	Appointed 1 April 2023 to present
Mr Earl Harper, Chief Commercial Officer	Appointed 1 June 2022 to present
Mr Clifton Smyth, Chief Business Development Officer	Appointed 9 November 2022 to present
Doug Hunt, Chief Operating Officer	Appointed 1 July 2023 to present

### REMUNERATION POLICY

The Company's remuneration policy for its KMP has been developed by the Board taking into account the size of the Company, the size of the management team, the nature and stage of development of the Company's current operations, and market conditions and comparable salary levels for companies of a similar size and operating in similar sectors.

In addition to considering the above general factors, the Board has also placed emphasis on the following specific issues in determining the remuneration policy for KMP:

- Sales contract awards;
- Technology development milestones; and
- The performance of the Company's shares as quoted on the Australian Securities Exchange.

### REMUNERATION COMMITTEE

Due to the current size of the Company, the Board did not implement a Remuneration Committee during the year, as such the Board of Directors of the Company is responsible for determining and reviewing compensation arrangements for the Directors and the executive team.

### REMUNERATION STRUCTURE

In accordance with best practice corporate governance, the structure of Non-Executive Director and executive remuneration is separate and distinct.

## NON-EXECUTIVE DIRECTOR REMUNERATION

The Board seeks to set aggregate remuneration at a level that provides the Company with the ability to attract and retain Directors of the highest calibre, whilst incurring a cost that is acceptable to shareholders.

The ASX Listing Rules specify that the aggregate remuneration of Non-Executive Directors shall be determined from time to time by a general meeting. The Constitution states that the Company may pay to the Non-Executive Directors a maximum total amount of director's fees, determined by the Company in general meeting, or until so determined, as the Directors resolve. Fees for the Non-Executive Directors' are presently set at \$350,000 per annum including superannuation. These fees cover main board activities only. Non-Executive Directors may receive additional remuneration for other services provided to the Company.

The Non-Executive salary remuneration became effective from the date of the appointment of the Company to the Official List of the Australian Securities Exchange.

## EXECUTIVE REMUNERATION

The Company's remuneration policy is to provide a fixed remuneration component and a short- and long-term performance-based component. The Board believes that this remuneration policy is appropriate given the considerations discussed in the section above and is appropriate in aligning executives' objectives with shareholder and business objectives.

## FIXED REMUNERATION

Fixed remuneration consists of base salaries, as well as employer contributions to superannuation funds and other non-cash benefits. Fixed remuneration is reviewed annually by the Board. The process consists of a review of company and individual performance, relevant comparative remuneration externally and internally and, where appropriate, external advice on policies and practices.

## PERFORMANCE BASED REMUNERATION – SHORT TERM INCENTIVE

The Board has not implemented a system where Executives are entitled to annual cash bonuses. The Company may provide pay performance bonuses to Executives as determined by the Board from time to time.

## COMPANY PERFORMANCE SHARES AND RIGHTS

The Board has previously chosen to issue Performance Shares and Rights (where appropriate) to some executives as a key component of the incentive portion of their remuneration, in order to attract and retain the services of the executives and to provide an incentive linked to the performance of the Company.

## PERFORMANCE BASED REMUNERATION – LONG TERM INCENTIVE

In the future the Board may grant Options to executives and key consultants to provide incentive-based remuneration, with exercise prices at and/or above market share price (at the time of agreement). As such, Incentive Options granted to executives will generally only be of benefit if the executives perform to the level whereby the value of the Company increases sufficiently to warrant exercising the Incentive Options granted. It is considered the performance of the executives and the performance and value of the Company are closely related.

Vesting conditions associated with certain other performance rights and options have been set to align with selected strategic objectives of the Group that are considered relevant to the role of the individual to whom they are granted. Should these objectives be achieved, they are expected to have a positive impact on the performance of the Group and result in increased value for shareholders.

The Company prohibits executives entering into arrangements to limit their exposure to Performance Shares or Incentive Options granted as part of their remuneration package.

## Long-Term Incentive Plans

The Company has implemented an Employee Incentive Plan, a Loan Funded Share Plan, the Director and Employee, the ClearVue Officer, Employee and Adviser Share Plan and the Incentive Option Plan.

### *Employee Incentive Plan*

Under the Employee Incentive Plan, the Company may grant options to subscribe for Shares entitling the holder to be issued Shares on terms and conditions set by the Board at its discretion.

The material terms of the Employee Incentive Plan are as follows:

- a. The purpose of the Plan is to:
  - assist in the reward, retention and motivation of eligible persons;
  - to align the interests of eligible persons more closely with the interests of shareholders, by providing an opportunity for eligible persons to receive an equity interest in the form of Awards; and
  - to provide eligible persons with the opportunity to share in any future growth in value of the Company.



- b. The following persons can participate in the Plan if the Board makes them an offer to do so:
- a director;
  - a full-time or part-time employee;
  - a contractor; or
  - a casual employee of the Company or an associated body corporate and includes a person who may become an eligible person within (a) above subject to accepting an offer of engagement for that role.
- c. Plan Options issued under the Plan are subject to the terms and conditions set out in the Rules, which include:
- Vesting Conditions – which are time-based criteria, requirements or conditions (as specified in the offer and determined by the Board) which must be met prior to Awards vesting in a participant, which the Board may throughout the course of the period between the grant of an Award and its vesting, waive or accelerate as the Board considers reasonably appropriate;
  - Performance Conditions – which are conditions relating to the performance of the Group and its related bodies corporate (and the manner in which those conditions will be tested) as specified in an offer and determined by the Board; and
  - Exercise Conditions – which are criteria, requirements or conditions, as determined by the Board or under the Plan, which must be met (notwithstanding the satisfaction of any Vesting Conditions and/or Performance Conditions) prior to a Participant being entitled to exercise vested Awards in accordance with clauses 8 and 9 of the plan. Clause 8 prohibits the disposal of any incentive plan 12 months from the date the Plan Shares were issued to the holder, unless there is prior written approval of the Directors, or pursuant to an IPO or Takeover. Subject to the approval of the Directors, the employee may request that Plan Shares be allotted to a Related Entity of the employee under Clause 9.
- d. In accordance with ASIC Class Order 14/1000, the total Awards that may be issued under the Plan will not exceed 5% of the total number of Shares on issue. In calculating this limit, Awards issued to participants under the Plan other than in reliance upon this Class Order are discounted.
- e. The Board has the unfettered and absolute discretion to administer the Plan.
- f. Awards issued under the Plan are not transferable and will not be quoted on the ASX.

The Rules otherwise contain terms and conditions considered standard for long-term incentive plan rules of this nature.

There were no options issued under the Employee Incentive Plan during the year (2023: Nil).

### **Loan Funded Share Plan**

Under the Loan Funded Share Plan, the Company may grant Shares to a participant and may provide a loan to facilitate the acquisition of the Plan Shares. The terms of the loan and price of the Shares is determined by the Board.

The material terms of the Loan Funded Share Plan are as follows:

- a. The purpose of the Plan is to:
- assist in the reward, retention and motivation of eligible persons;
  - to align the interests of eligible persons more closely with the interests of shareholders, by providing an opportunity for eligible persons to increase their ownership interest in the Company; and
  - to provide eligible persons with the opportunity to share in any future growth in value of the Company.
- b. The following persons can participate in the Plan if the Board makes them an offer to do so:
- a director;
  - a full-time or part-time employee;
  - any other person who the Board determines is eligible to participate in the Plan.
- c. Loans offered under the Plan to facilitate the acquisition of Plan Shares will be interest free and end on 10 years from the Share Grant Date, or earlier in accordance with the Plan Rules.
- d. The total Shares that may be issued under the Plan in the previous five years, excluding any offers made in accordance with s708 of the Corporations Act, will not exceed 10% of the total number of Shares on issue.
- e. The Board has the unfettered and absolute discretion to administer the Plan.
- f. Shares issued under the Plan are not transferable.

The Rules otherwise contain terms and conditions considered standard for loan funded share plan rules of this nature.

There were no Shares issued under the Loan Funded Share Plan during the current financial year.

During the year ended 30 June 2017, shares were issued under the Loan Funded Share Plan to then members of the Board. The following loans outstanding at 30 June 2024 and at the date of this report. Such loans are to be settled on or before 19 September 2027.

HOLDER	POSITION	NO. OF SHARES	LOAN AMOUNT
Mr Victor Rosenberg	Executive Chairman	1,000,000	\$150,000
Mr Jamie Lyford	Former Executive Director	1,950,000	\$292,000
Mr Ian Rosenberg	Former Non-Executive Director	125,000	\$18,750

The remuneration report details the remuneration arrangements for KMP who are defined as those persons having authority and responsibility for planning, directing and controlling the major activities of the Company, directly or indirectly, including any Director (whether executive or otherwise) of the Company.

#### ***ClearVue Officer, Employee and Adviser Share Plan***

The Company has also adopted a share plan called the 'ClearVue Officer, Employee and Adviser Share Plan' (OEASP) pursuant to which the Company may issue shares in the Company to participants. The difference between the OEASP and the Loan Funded Share Plan is that participants in the OEASP can be issued Shares at no cost and without loans being made by the Company. The OEASP was approved by Shareholders on 13 April 2017 (and is referenced at page 141 of the IPO Prospectus). A summary of the rules of the OEASP is set out below:

- a. (Eligibility): The Company may issue Shares to full time or part time officers, employees and advisers of the Company or any associated body corporate, or any other person who the Board determines is eligible to participate in the OEASP.

- b. (Consideration): No subscription price is payable for Shares issued under the OEASP. Shares issued under the OEASP vest on issue but cannot be transferred for 12 months. The Board may waive the transfer restrictions, including in circumstances where a takeover offer is made for the Company. Shares issued under the OEASP carry with them the same rights to vote and receive dividends or capital distributions as other ordinary shares of the Company which are on issue.

The remuneration report details the remuneration arrangements for KMP who are defined as those persons having authority and responsibility for planning, directing and controlling the major activities of the Company, directly or indirectly, including any Director (whether executive or otherwise) of the Company.

No shares were issued to key management personnel or directors under this plan for the year.

#### ***Director and Employee Fee plan***

The Company has adopted a Director and Employee Fee Plan (Fee Plan) to enable the Company to issue Shares to eligible participants in lieu of accrued cash remuneration. Eligible participants are full or part-time employees, officers, consultants, contractors and directors of the Company or any related entity or any nominee of such parties. Under the Fee Plan, eligible participants can elect to be paid some or all of the cash remuneration accrued to them by the issue of Shares. Any issues of Shares then made are at the discretion of the Board. The Fee Plan was approved by shareholders on 2 November 2020.

There were no shares issued under the Fee Plan during the year.

**Employee Securities Incentive Plan**

The Company has adopted an Employee Securities Incentive Plan (ESIP) to enable the Company to issue Options, Performance Rights, Shares and / or Loan Funded Shares to eligible participants.

Eligible participants are any Director or a person who is a full-time or part-time employee of the Company or its Related Bodies Corporate who is declared by the Board in its sole and absolute discretion to be eligible and any other person providing services to the Group and who is declared by the Board in its sole and absolute discretion to be eligible.

The material terms of the Employee Incentive Plan are as follows:

**a. The purpose of the Plan is to:**

- assist in the reward, retention and motivation of eligible persons;
- to align the interests of eligible persons more closely with the interests of shareholders, by providing an opportunity for eligible persons to receive an equity interest in the form of Awards; and
- to provide eligible persons with the opportunity to share in any future growth in value of the Company.

**b. Terms of Options and Performance Rights**

Each Option and/or Performance Right (Convertible Security) represents a right to acquire one or more Shares (for example, under an option or performance right), subject to the terms and conditions of the Plan. Prior to a Convertible Security being exercised a Participant does not have any interest (legal, equitable or otherwise) in any Share the subject of the Convertible Security by virtue of holding the Convertible Security. A Participant may not sell, assign, transfer, grant a security interest over or otherwise deal with a Convertible Security that has been granted to them unless otherwise determined by the Board. A Participant must not enter into any arrangement for the purpose of hedging their economic exposure to a Convertible Security that has been granted to them.

**c. Share Awards**

The Board may from time to time make an invitation to an Eligible Participant to acquire Share Awards under the Plan. The Board will determine in its sole and absolute discretion the acquisition price (if any) for each Share Award which may be nil. The Share Awards may be subject to performance hurdles and/or vesting conditions as determined by the Board. Where Share Awards granted to a Participant are subject to performance hurdles and/or vesting conditions, the Participant's Share Awards will be subject to certain restrictions until the applicable performance hurdles and/or vesting conditions (if any) have been satisfied, waived by the Board or are deemed to have been satisfied under these Rules. Following the issue of a vesting notification to the Participant, the Share Awards held by the Participant will no longer be subject to any restrictions and may be transferred or sold by the Participant, subject to compliance with applicable laws, the Company's Securities Trading Policy and the terms of the Plan.

During the year ended 30 June 2024, 1,000,000 options and 5,000,000 performance rights were issued to key management personnel under the plan. (4,000,000 shares and 500,000 options were issued under the plan during the prior year)

The conversion of the performance rights is dependent on the following:

**i) Class A Performance Rights**

- In the event that the aggregate of the value of the ClearVue (Orders and the ClearVue Payments is equal to or greater than \$2,000,000 within a period of 24 months commencing on the date of issue of the Performance Rights (Issue Date) (Class A Milestone 1), each Class A Performance Right will vest and be convertible into one Share; or
- in the event that Class A Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$7,000,000 within a period of 36 months from the Issue Date (Class A Milestone 2), each Class A Performance Right will vest and be convertible into one Share; or
- in the event that neither Class A Milestone 1 or Class A Milestone 2 is satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Issue Date, each Class A Performance Right will vest and be convertible into one Share.



**ii) Class B Performance Rights**

- In the event that the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$5,000,000 within a period of 24 to 36 months from the Issue Date (Class B Milestone 1), each Class B Performance Right will vest and be convertible into one Share; or
- in the event that Class B Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$7,000,000 within a period of 36 months from the Issue Date (Class B Milestone 2), each Class B Performance Right will vest and be convertible into one Share; or
- in the event that neither Class B Milestone 1 or Class B Milestone 2 is satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Issue Date, each Class B Performance Right will vest and be convertible into one Share.

**iii) Class C Performance Rights**

- In the event that the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$10,000,000 within a period of 36 to 48 months from the Issue Date (Class C Milestone 1), each Class C Performance Right will vest and be convertible into one Share; or
- In the event that Class C Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Issue Date, each Class C Performance Right will vest and be convertible into one Share.

**iv) Class D Performance Rights**

- In the event that the participant assisting the company completes the development and testing of vision and spandrel glass to achieve an A2 SO D1 fire rating confirmed by an independent third party testing, with such testing party approved by the company and certified to the EN13501.1 standard before the expiry date, each class D performance right will vest and be convertible into a share.

**v) Class E Performance Rights**

- In the event that the participant introduces an equity investor to the company where the equity investment transaction is concluded and / or the participant has carriage of concluding an equity investment transaction before the expiry date, each of the class E performance rights will vest and be convertible into a share.

**vi) Class F Performance Rights**

- In the event that the participant introduces an equity investor to the company where the equity investment transaction is concluded and / or the participant has carriage of concluding an equity investment transaction before the expiry date, each of the class E performance rights will vest and be convertible into a share.

**vii) Class G Performance Rights**

- In the event that the participant assists the company to complete an up-listing of its OTCQB US or ASX listing into the main US board of the NASDAQ or the NYSE before the expiry date or have commenced at least 3 months before the expiry date and such up-listing is completed within a further 6 months after the end of the expiry date, each of the class G performance rights will vest and be convertible into a share.

**viii) Class H Performance Rights**

- In the event the share price for the ordinary shares of the company reaches \$0.50 and maintains a volume weighted average of \$0.50 per ordinary share for at least 14 days with and before the expiry date, each of the class H performance rights will vest and be convertible into a share.

**ix) Class I Performance Rights**

- In the event that the company receives revenue of AUD\$1,500,000 from the sale of its own products (incorporating the ClearVue technology) during a twelve month period before the expiry date, each of the class E performance rights will vest and be convertible into a share

**x) Class J Performance Rights**

- In the event that the company receives revenue of AUD\$1,500,000 from the sale of its own products (incorporating the ClearVue technology) during a twelve month period before the expiry date, each of the class E performance rights will vest and be convertible into a share.

**d. Loan Funded Shares**

The Board may from time to time make an invitation to an Eligible Participant to acquire Loan Funded Shares under the Plan. The Board will determine in its sole and absolute discretion the acquisition price (if any) for each Loan Funded Shares which may be nil. The Loan Funded Shares may be subject to performance hurdles and/or vesting conditions as determined by the Board. Where Loan Funded Shares granted to a Participant are subject to performance hurdles and/or vesting conditions, the Participant's Loan Funded Shares will be subject to certain restrictions until the applicable performance hurdles and/or vesting conditions (if any) have been satisfied, waived by the Board or are deemed to have been satisfied under these Rules. Following the issue of a vesting notification to the Participant, the Loan Funded Shares held by the Participant will no longer be subject to any restrictions and may be transferred or sold by the Participant, subject to compliance with applicable laws, the Company's Securities Trading Policy and the terms of the Plan. When the Company makes an Invitation to an Eligible Participant to acquire Loan Funded Shares, the Company will also offer the Eligible Participant a Loan on terms and conditions to be determined by the Board, for the amount of the acquisition price of the Loan Funded Shares, for the purposes of acquiring all or part of the Loan Funded Shares the subject of the invitation. The loan amount may accrue interest as determined by the Board

No shares were issued under the plan during the year (no shares were issued under this plan during the prior year).

**Incentive Option plan**

The Company has adopted an Incentive Option Plan to enable the company grant Options to any Director, full or part time employee, or casual employee or contractor who falls within ASIC Class Order 14/1000, of the Company or an associated body corporate (Eligible Participant).

The material terms of the Employee Incentive Plan are as follows:

- a. The purpose of the Plan is to:
  - assist in the reward, retention and motivation of eligible persons;
  - to align the interests of eligible persons more closely with the interests of shareholders, by providing an opportunity for eligible persons to receive an equity interest in the form of Awards; and
  - to provide eligible persons with the opportunity to share in any future growth in value of the Company.

- b. The Board may, from time to time, in its absolute discretion, make a written offer to any Eligible Participant (including an Eligible Participant who has previously received an Offer) to apply for Options, upon the terms set out in the Plan and upon such additional terms and conditions as the Board determines (Offer).
- c. In exercising that discretion, the Board may have regard to the following (without limitation):
  - i) the Eligible Participant's length of service with the Group;
  - ii) the contribution made by the Eligible Participant to the Group;
  - iii) the potential contribution of the Eligible Participant to the Group; or
  - iv) any other matter the Board considers relevant.
- d. For the avoidance of doubt, nothing in this document obliges the Company at any time to make an Offer, or further Offer, to any Eligible Participant.
- e. All offers and sales of Options shall be in compliance with U.S. securities laws, if applicable, as well as securities laws of states within the U.S., to the extent applicable.

During the year, 4,000,000 options were issued under the plan (3,000,000 options were issued during the prior year).

**EXECUTIVE DIRECTOR SERVICE AGREEMENTS**

The Company entered into employment agreements with both Mr V Rosenberg and Mr Lyford dated 18 January 2018 respectively (both varied by letter on 1 January 2020), pursuant to which the Company had previously engaged Mr V Rosenberg as Executive Chairman and Mr Lyford as Executive Director. Mr Lyford resigned as a director on the 25 August 2020 and was appointed the Chief Operating Officer and General Counsel. Mr Lyford was reappointed as Executive Director on 10 February 2023 and remains as Chief Legal Officer. Mr Rosenberg resigned as Executive Chairman on 15 March 2023 and continued as the Non-Executive Chairman.

The material terms and conditions of the Employment Agreements are summarised below:

- a. Term: The Employment Agreements commenced on the date of the Company's admission to the Official List (on 23 May 2018) and each Employment Agreement continues until terminated in accordance with its terms. The Employment Agreements were varied on 12 December 2023 with variations becoming effective 1 January 2024.
- b. Remuneration: From 1 January 2024, Mr Lyford received annual salaries and director's fees exclusive of statutory superannuation of approximately \$320,000.
- c. Incentive Programs: The Executives may participate in any incentive plan that the Company may introduce from time to time.
- d. Termination: The Company may immediately terminate the employment of Mr V Rosenberg and Mr Lyford by written notice for a number of standard events including, but not limited to, if at any time such Executive:
  - i) commits a serious or repeated or continual breach of the obligations under their Executive Agreement;
  - ii) is guilty of any serious misconduct or serious neglect or dishonesty in the discharge of their duties under their Executive Agreement; or
  - iii) act in a manner which, in the reasonable opinion of the Company, brings the name or reputation of the Company or any member of the Company group into serious disrepute or prejudices the interests of the business of the Company.

The Company or the Executives may terminate the Executive Agreements for any reason by giving 6 months' written notice. The Employment Agreements contains other standard terms and conditions expected to be included in contracts of this nature.

## RELATIONSHIP BETWEEN REMUNERATION OF KMP AND SHAREHOLDER WEALTH AND EARNINGS

The Board anticipates that the Company will retain earnings (if any) and other cash resources for the development of its business activities. The Company does not currently have a policy with respect to the payment of dividends and returns of capital however this will be reviewed on and in relation to, the nature and amount of remuneration of KMP and dividends paid and returns of capital by the Company during the current and previous four financial years.

The Company did not consider appreciation of the Company's shares when setting remuneration.

The Board did issue Performance Shares and Performance Rights to Key Management Personnel and has implemented a Loan Funded Share Plan which will generally be of value if the Company's shares appreciate over time. However, it should be noted that all Director Shares granted under the Loan Funded Share Plan and all Performance Shares had been imposed in escrow (sale) restriction period for two years after listing. This is in line with the Company policy that Company securities be used for long term incentive for Directors.





## DIRECTOR'S REPORT

### REMUNERATION REPORT (CONTINUED)

#### AMOUNT OF REMUNERATION

Details of the remuneration of key management personnel of the consolidated entity are set out in the following tables. The proportion of remuneration linked to performance and the fixed proportion are as follows:

	FIXED REMUNERATION		AT RISK – STI		AT RISK – LTI	
	2024	2023	2024	2023	2024	2023
<b>DIRECTORS</b>						
Mr V Rosenberg	100%	100%	–	–	100%	100%
Mr Lyford	100%	100%	–	–	–	–
Mr Hoenicke	100%	100%	–	–	–	–
Mr Mowrey	100%	100%	–	–	–	–
<b>KEY MANAGEMENT PERSONNEL</b>						
Mr Deil (CEO)	100%	100%	–	–	100%	100%
Mr Edwards (CFO)	100%	100%	–	–	–	–
Mr Harper (CCO)	100%	100%	–	–	100%	100%
Mr Smyth (CBDO)	100%	100%	–	–	100%	100%
Mr Hunt (COO)	100%	100%	–	–	100%	100%

#### 2024

	SHORT-TERM BENEFITS				POST-EMPLOYMENT BENEFITS		LONG-TERM BENEFITS		EQUITY-SETTLED SHARE-BASED PAYMENTS		
	Salary, fees & leave	Profit share & bonus	Non-monetary	Other <sup>2</sup>	Super	Other	Incentive plans	Leave	Shares / units	Options / performance shares	TOTAL
DIRECTORS											
Mr V Rosenberg <sup>1</sup>	313,050	–	–	–	9,460	–	–	–	–	372,736	695,246
Mr Lyford	281,286	–	–	10,000	30,941	–	–	9,025	–	372,736	703,988
Mr Hoenicke	69,932	–	–	–	–	–	–	–	–	372,736	442,668
Mr Mowrey	210,540	–	–	–	–	–	–	–	–	372,736	583,276
KEY MANAGEMENT PERSONNEL											
Mr Deil (CEO)	421,256	–	–	–	66,483	–	–	–	–	99,410	587,149
Mr Edwards (CFO)	180,000	–	–	–	19,800	–	–	12,808	–	-	212,608
Mr Harper (CCO)	178,788	–	–	–	19,667	–	–	16,364	–	762,771	977,590
Mr Smyth (GBDO)	354,741	–	–	–	–	–	–	–	–	614,863	969,604
Mr Doug Hunt (COO)	245,334	50,000	–	–	–	–	–	–	–	491,713	787,047
	2,254,927	50,000	–	10,000	146,351	–	–	38,197	–	3,459,701	5,959,176

<sup>1</sup> Mr Rosenberg's salary fees and leave include a consulting fee to Luminate Pty Ltd (an entity associated with Mr Rosenberg) of \$227,050 and director's fee of \$86,000

<sup>2</sup> Relates to motor vehicle allowances

## 2023

	SHORT-TERM BENEFITS				POST-EMPLOYMENT BENEFITS		LONG-TERM BENEFITS		EQUITY-SETTLED SHARE-BASED PAYMENTS		
	Salary, fees & leave	Profit share & bonus	Non-monetary	Other*	Super	Other	Incentive plans	Leave	Shares / units	Options / performance shares	TOTAL
DIRECTORS											
Mr V Rosenberg <sup>1</sup>	410,100	–	–	7,083	30,909	–	–	(118,923)	–	–	329,169
Mr Steinepreis <sup>2</sup>	28,000	–	–	–	–	–	–	–	–	–	28,000
Mr Carmichael <sup>3</sup>	48,000	–	–	–	5,040	–	–	–	–	–	53,040
Mr Downes <sup>4</sup>	65,760	–	–	–	–	–	–	–	–	–	65,760
Mr Lyford <sup>5</sup>	75,003	–	–	3,836	7,875	–	–	5,192	–	–	91,906
Mr Hoenicke <sup>6</sup>	10,000	–	–	–	–	–	–	–	–	–	10,000
Mr Mowrey <sup>7</sup>	10,000	–	–	–	–	–	–	–	–	–	10,000
KEY MANAGEMENT PERSONNEL											
Mr Deil (CEO) <sup>8</sup>	35,980	–	–	–	–	–	–	4,088	–	10,593	50,661
Mr Lyford (COO) <sup>5</sup>	120,540	–	–	6,164	12,657	–	–	8,345	760,000	–	907,706
Mr Edwards (CFO) <sup>9</sup>	45,000	–	–	–	4,725	–	–	4,500	–	24,570	78,795
Mr Harper (CCO) <sup>10</sup>	163,636	–	–	–	17,182	–	–	13,217	–	–	194,035
Mr Smyth (GBDO) <sup>11</sup>	190,358	–	–	–	–	–	–	–	–	–	190,358
	1,202,377	–	–	17,083	78,388	–	–	(83,581)	760,000	35,163	2,009,430

\*Relates to motor vehicle allowances

1 Mr V Rosenberg retired from the positions of Executive Chairman and CEO, and continued as non-executive chairman effective 15 March 2023. Mr Rosenberg was paid a retirement benefit of 12 months base salary, including 6 months in lieu of notice period.

2 Mr Steinepreis resigned from the board effective 10 February 2023

3 Mr Carmichael resigned from the board effective 30 June 2023

4 Mr Downes resigned from the board effective 10 February 2023

5 Mr Lyford was appointed to the board effective 10 February 2023

6 Mr Hoenicke was appointed to the board effective 1 May 2023

7 Mr Mowrey was appointed to the board effective 1 May 2023

8 Mr Deil was appointed to the board effective 1 June 2023

9 Mr Edwards was appointed CFO effective 1 April 2023

10 Mr Harper was appointed CCO effective 1 June 2022

11 Mr Smyth was appointed CBDO effective 9 November 2022. Mr Smyth was employed by way of his consulting company based in the UK, CTS Consultants Pty Ltd

## DIRECTOR'S REPORT

### REMUNERATION REPORT (CONTINUED)

#### PERFORMANCE SHARES

No performance shares were issued as remuneration to directors and other key management personnel in this financial year. Refer to Related Party Transaction note for details of options issued to associates of Directors.

#### OPTIONS

During the year, 1,000,000 options were issued to key management personnel during the year and 3,500,000 options were issued during the prior year. Refer to Related Party Transaction note for details of options issued to associates of Directors.

#### SHAREHOLDING

The number of shares held during the financial year by each director and members of key management personnel of the Company, including their personally related parties, is set out below:

#### ORDINARY SHARES

	BALANCE AT THE START OF THE YEAR / APPOINTMENT DATE	RECEIVED AS PART OF REMUNERATION	ADDITIONS	DISPOSALS / OTHER	BALANCE AT THE END OF THE YEAR / RESIGNATION DATE
<b>DIRECTORS</b>					
Mr V Rosenberg	27,070,198	–	60,000	–	27,130,198
Mr Lyford	9,456,618	–	20,000	–	9,476,618
Mr Hoenicke	–	–	236,900	–	236,900
Mr Mowrey	–	–	200,000	–	200,000
	<b>36,526,816</b>	<b>–</b>	<b>516,900</b>	<b>–</b>	<b>37,043,716</b>
<b>KEY MANAGEMENT PERSONNEL</b>					
Mr Deil	–	–	2,084,000	–	2,084,000
Mr Edwards	–	–	40,000	–	40,000
Mr Harper	675,000	–	40,000	–	715,000
My Smyth	–	–	–	–	–
	<b>675,000</b>	<b>–</b>	<b>2,164,000</b>	<b>–</b>	<b>2,839,000</b>





## CONVERTIBLE SECURITY HOLDING

The number of convertible securities held during the financial year by each director and members of key management personnel of the Company, including their personally related parties, is set out below:

### OPTIONS

	BALANCE AT THE START OF THE YEAR / APPOINTMENT DATE	GRANTED	EXERCISED	FREE ATTACHING OPTIONS	BALANCE AT THE END OF THE YEAR / RESIGNATION DATE
<b>DIRECTORS</b>					
Mr V Rosenberg	–	1,000,000	–	20,000	1,020,000
Mr Hoenicke	–	1,000,000	–	–	1,000,000
Mr Mowrey	–	1,000,000	–	66,667	1,066,667
Mr Lyford	–	1,000,000	–	6,666	1,006,666
	–	4,000,000	–	93,333	4,093,333
<b>KEY MANAGEMENT PERSONNEL</b>					
Mr Deil	3,000,000	–	–	333,333	3,333,333
Mr Edwards	500,000	–	–	13,333	513,333
Mr Harper	–	500,000	–	13,333	513,333
Mr Hunt	–	500,000	–	–	500,000
	3,500,000	1,000,000	–	359,999	4,859,999

### PERFORMANCE RIGHTS

	BALANCE AT THE START OF THE YEAR/ APPOINTMENT DATE	GRANTED	EXERCISED	EXPIRED / FORFEITED / OTHER	BALANCE AT THE END OF THE YEAR / RESIGNATION DATE
<b>DIRECTORS</b>					
Mr V Rosenberg	10,000,000	–	–	–	10,000,000
	10,000,000	–	–	–	10,000,000
<b>KEY MANAGEMENT PERSONNEL</b>					
Mr Smyth	–	2,000,000	–	–	2,000,000
Mr Harper	–	2,000,000	–	–	2,000,000
Mr Hunt	–	1,000,000	–	–	1,000,000
	–	5,000,000	–	–	5,000,000

500,000 unlisted options each were issued to Mr Hunt and Mr Harper with an expiry date of 30 October 2027, that vest on the condition the share price of the Company reaches \$0.50 and maintains a VWAP of \$0.50 for at least 14 days within and prior to the expiry.

The options issue in the prior year comprise of vesting milestones of 500,000 tranche 1 options (VWAP of AUD \$1.00 per Share for at least 30 days), 500,000 tranche 2 options (introduction and procuring a strategic alliance), 500,000 tranche 3 options (VWAP of AUD \$1.50 per share for at least 30 days), 500,000 tranche 4 options (securing a commercial deployment) and 1,000,000 tranche 5 options (commence up-listing of its OTCQB US listing onto the NASDAQ), within 18 months from date of grant. Options were issued under the Company's incentive option plan.

## OTHER TRANSACTIONS WITH KEY MANAGEMENT PERSONNEL AND THEIR RELATED PARTIES

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Legal services from Steinepreis Paganin <sup>1</sup>	–	30,078
Company secretarial services from Ventnor Capital Pty Ltd <sup>2</sup>	–	63,400
Consultancy services from Luminate Pty Ltd <sup>3</sup>	227,050	70,000

1 Director-related entity of Mr Steinepreis

2 Director-related entity of Mr Carmichael

3 Director related entity of Mr Rosenberg. This consulting fee has been included in the salaries fee and levies.

Receivable from and payable to related parties.

All transactions were made on normal commercial terms and conditions and at market rates.

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Trade payable to Ventnor Capital Pty Ltd <sup>1</sup>	–	5,500
Accrual to Mr Deil	–	35,980
Accrual to Gerd Hoenicke	40,000	8,000
Accrual to Charles Mowrey	–	8,000
Share plan reserve to Mr V Rosenberg <sup>2</sup>	150,000	150,000
Share plan reserve to Mr S Rosenberg <sup>3,6</sup>	–	18,750
Share plan reserve to Mr I Rosenberg <sup>3,6</sup>	18,750	18,750
Share plan reserve to Mr Lyford <sup>4</sup>	292,500	292,500
Accrual to Luminate Pty Ltd <sup>5</sup>	8,705	10,000

1 Director-related entity of Mr Carmichael

2 For the purchase of 1,000,000 shares at an issue price of \$0.15

3 For the purchase of 125,000 shares at an issue price of \$0.15

4 For the purchase of 1,950,000 shares at an issue price of \$0.15

5 Director related entity of Mr V Rosenberg

6 Former key management personnel, further details provided on page 15

– End of Remuneration Report –

## PRINCIPAL ACTIVITIES

The principal activities of the Company during the year were developing a sales and leads pipeline for the Company's products, licensing activities to appoint new manufacturers and distributors, as well as research and development activities applied to the Company's world leading solar glass technology. There were no significant changes in the nature of the activities of the Company during the financial year.

## REVIEW OF OPERATIONS AND FINANCIAL RESULTS

The operating loss of the Group for the financial year after providing for income tax amounted to \$12,491,036 (2023: \$7,497,092), with net cash used in operating activities of \$7,904,536 (2023: \$5,453,878).

### Commercial agreements

#### **Commercial launch in the United States**

ClearVue commercially entered the United States in October with A\$252k contract to supply solar glass solutions for a greenhouse project run by Greenhouse System USA Inc. of Watsonville, California, a leading designer and manufacturer of greenhouses in North America. This was followed by a repeat order in July, valued at A\$175k, for Greenhouse System USA to create a demonstrator greenhouse to be used by System USA to exhibit and highlight the benefits of the ClearVue technology.

#### **Commercial launch in Australia**

ClearVue's first commercial order in Australia was with property developer Kapitol Group to incorporate ClearVue's Generation 2 solar windows into the façade of the Construction, Forestry, Maritime, and Employees Union (CFMEU) Training and Wellness Centre in Melbourne. The solar glazing units were manufactured and installed in May, with the technology specified by award-winning architect Hayball for its sustainability benefits and high performance. This is the first project in Australia to specify ClearVue's unique solar glazing technology within the project design.

### North American operations

ClearVue solidified its presences in North America with the appointment of Charles (Chuck) Mowrey President and CEO North America, a dedicated headquarters in California to service the North American market, and now able to trade on the OTCQX® Best Market. Mr Mowrey transferred to his executive role within the company on 1 May 2024, having previously served as a Non-Executive board member since 1 May 2023. Mr Mowrey continues to serve on the board as an Executive Director. Qualifying to trade on the OTCQX® Best Market aligns with the Company's targeting of the US market for customers of ClearVue's world-leading products and technologies as well as for US based investors.

## Global manufacturing and distribution agreements

During the year ClearVue signed significant manufacturing and/or distribution agreements with minimum sales commitments with leading providers in key markets around the world. These include: Greendustrial Global in Israel, H T Glass in Singapore, Concept Business Solutions in South Africa, and 8G Solutions for the US states of Colorado and Arizona and MS Glass in Australia.

## Certifications, testing and R&D

### **Certifications**

During the year ClearVue achieved critical certifications for its products, ensuring compliance with many international building codes and regulations essential for ClearVue's vision glass products to be included in building design specifications, enhancing confidence among architects and specifiers globally.

Certifications include:

- Insulating Glazing Certification Council (IGCC) – seal certification
- EN13501-1 – combustibility with rating confirmed to an industry leading rating of A2-s1, d0
- Low combustibility fire certification as required for buildings over 18 metres and in high-risk environments such as hospitals, schools, and hotels.
- IEC 61730 – electrical, heat, fire and seal
- IEC 61215 – electrical and seal.

### **Energy efficiency testing**

In October 2023, Singapore's Building and Construction Authority (BCA) Skylab facility confirmed ClearVue's solar glass technology offers significant energy savings when compared against BCA's 'Greenmark Platinum' rated double-glazed low-e product. Testing results demonstrated substantial benefits for building owners and developers including:

- 22.8% reduction in cooling load and 7.5% overall energy savings after accounting for energy generation (Gen-2 IGUs only)
- 71% overall energy savings achieved with the addition of ClearVue's recently announced Spandrel Solution (Gen-2 IGUs plus the Spandrel Solution)
- Improved thermal comfort for building occupants (PMV index within ASHRAE comfort zone for 96.1% of time)
- Improvement in imperceptible glare (75.2% of the time v 45.8% for reference cell)
- The integration of Gen-2 PV IGU technology led to lower greenhouse gas emissions and a reduced carbon footprint for buildings.



## InterTek safety tests for new PVB materials

ClearVue developed several novel fluorescent nano- and micro-particle-loaded PVB materials to improve energy harvesting performance. Testing for the PVB interlayer incorporating these particles passed stringent tests at Intertek showing compliance with ANSI Z97.1 standards (safety and long-term stability of glass laminates). The tests also confirmed compliance with light transmittance, low haze and correct colour representation standards. This is a crucial process to enable the application of these novel nano- and micro-particle formulations in PVB, making them appropriate for commercial laminated glass in business structures.

ClearVue also commenced R&D discussions with Lawrence Berkeley National Laboratory and the US National Renewable Energy Laboratory to explore the optical properties and radiative cooling potential of the nano- and micro-particle-loaded interlayers formulations. ClearVue anticipates this will result in further SHGC (solar heat gain coefficient) reductions for future ClearVue window products and may give rise to new product categories.

## Collaboration with LuxWall to create the world's first net zero focused window

ClearVue entered into a Collaboration Agreement with vacuum insulated glazing supplier LuxWall in the US to develop and commercialise the 'Zero Window'. The Zero Window combines ClearVue's photovoltaic solar glazing and LuxWall's advanced vacuum insulated glazing into one product, expected to thermally outperform all existing double-glazed low emissivity solutions while generating power from the glass.

## Sales and marketing

During the year ClearVue finalised an expanded range of Building Integrated Photovoltaic (BIPV) products, now branded as the ClearVue Power Facade™. This includes solar spandrel, solar cladding, and architectural BIPV (skylight and balustrading glass), designed to cover nearly all façade surfaces.

The ClearVue Power Facade™ was launched at the AIA24 Conference on Architecture & Design in Washington DC. A comprehensive product catalogue and brochures for the expanded product range have been shared with licensees to support their sales efforts, and to potential customers.

ClearVue developed new licensee sales tools to support sales, including:

- a new high-rise archetype for use by international licensees, building and architectural firms which demonstrates a new energy model validated across 15 global locations showing how the ClearVue Power Façade products when deployed across and throughout the façade can meet or exceed the energy needs of the building
- an independent US tax study to support US sales for use by US licensees, highlighting substantial federal tax incentives for end-customers deploying ClearVue products including: eligibility for energy credits and deductions, investment tax credit, energy efficient commercial buildings deduction, bonus opportunities (project bonus, domestic content bonus, energy community bonus, low-income community bonus).
- the development of a new Custom Flash Tester for use by licensed manufacturers to certify the power performance of manufactured Generation 2 solar PV glazing. This technology will ensure the quality of ClearVue branded solar IGUs by confirming the power generation and electrical performance of each individual glazing product without removing the glass from the production line, lowering the rate of production or impacting line productivity.

## ADDITIONAL INFORMATION

	2024	2023	2022	2021	2020
Revenue	39,811	63,310	287,613	–	–
EBITDA	(11,906,897)	(7,127,567)	(3,583,633)	(6,682,951)	(1,854,429)
EBIT	(12,514,067)	(7,484,316)	(3,791,365)	(6,878,110)	(2,021,190)
Loss after income tax	(12,491,037)	(7,497,092)	(3,806,151)	(6,900,493)	(2,049,191)
Share price (\$)	0.41	0.165	0.20	0.44	0.125
Dividend (cents per share)	–	–	–	–	–
Basic loss per share (cents per share)	(5.4)	(3.5)	(1.8)	(4.7)	(1.8)

## DIVIDENDS

No dividend has been declared or paid since the start of financial year. The Directors do not recommend the declaration of a dividend.

## SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS

No significant changes in state of affairs from prior year.

## EVENTS SUBSEQUENT TO THE END OF THE REPORTING PERIOD

On the 8 July 2024 the "At-Call Funding" facility exercised 5,000,000 shares for a gross equity raise of \$2,733,000 (\$2,596,350 after fees).

On 25 July 2024 125,000 fully paid ordinary shares were issued on the conversion of options at \$0.30 each.

No other matters or circumstances have arisen since 30 June 2024 that has significantly affected, or may significantly affect the Company's operations, the results of those operations, or the Company's state of affairs in future financial years.

## FUTURE DEVELOPMENTS

A discussion of likely developments in the Company's and the expected results of those operations is set out in the Executive Chairman's Letter.

## DIRECTORS' MEETINGS

The meetings of the Company's Board of Directors held during the year ended 30 June 2024. The number of meetings attended by each director were:

	BOARD MEETING		AUDIT & COMPLIANCE COMMITTEE MEETINGS <sup>1</sup>	
	Eligible to attend	Attended	Eligible to attend	Attended
Mr V Rosenberg	7	7	-	-
Mr Lyford	7	7	-	-
Mr Hoenicke	7	6	-	-
Mr Mowrey	7	7	-	-

<sup>1</sup> Committee meetings are performed by the Board as a whole.

During the financial year, the Directors also met regularly on Company matters on an informal basis.

## ENVIRONMENTAL REGULATIONS

The Group's operations are not regulated by any significant environmental regulation under a law of the commonwealth or of a State or Territory of Australia.

## INDEMNIFYING OFFICER OR AUDITOR

No indemnities have been given or agreed to be given or insurance premiums paid or agreed to be paid, during or since the end of the financial year, to any person who is or has been an officer or auditor of the Company.

## PROCEEDINGS ON BEHALF OF COMPANY

No person has applied for leave of Court to bring proceedings on behalf of the Group or intervene in any proceedings to which the Group is party for the purpose of taking responsibility on behalf of the Group for all or any part of those proceedings. The Group was not a party to any proceedings during the year.

## NON-AUDIT SERVICES

There were no provisions of non-audit services to the Company during the financial year, by the auditor.

## AUDITOR'S INDEPENDENCE DECLARATION

A copy of the Auditor's Independence Declaration as required under section 307C of the Corporations Act 2001 has been included.

Signed in accordance with a resolution of the Board of Directors.



**Victor Rosenberg**  
Non-Executive Chairman

Perth WA

Date: 30 September 2024



**Grant Thornton Audit Pty Ltd**  
Level 43 Central Park  
152-158 St Georges Terrace  
Perth WA 6000  
PO Box 7757  
Cloisters Square  
Perth WA 6850  
T +61 8 9480 2000

## Auditor's Independence Declaration

### To the Directors of ClearVue Technologies Limited

In accordance with the requirements of section 307C of the *Corporations Act 2001*, as lead auditor for the audit of ClearVue Technologies Limited for the year ended 30 June 2024, I declare that, to the best of my knowledge and belief, there have been:

- a no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- b no contraventions of any applicable code of professional conduct in relation to the audit.

A stylized signature of "Grant Thornton" in a cursive font, enclosed in a light grey rectangular box.

GRANT THORNTON AUDIT PTY LTD  
Chartered Accountants

A stylized signature of "J C Rubelli" in a cursive font, enclosed in a light grey rectangular box.

J C Rubelli  
Partner – Audit & Assurance

Perth, 30 September 2024

**[www.grantthornton.com.au](http://www.grantthornton.com.au)**  
**ACN-130 913 594**

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389. 'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards Legislation.



# CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE YEAR ENDED 30 JUNE 2024

	NOTE	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Revenue from contracts with customers		39,811	63,310
Other income	14	1,193,266	1,152,716
		<b>1,233,077</b>	<b>1,216,026</b>

EXPENSES			
Consulting expense		(3,495,291)	(2,629,563)
Depreciation and amortisation expense		(630,190)	(343,971)
Employee benefits expense		(2,371,850)	(1,566,054)
Finance costs	15	23,025	(12,777)
Legal fees		(124,721)	(72,447)
Material costs		(719,377)	(618,851)
Royalty expense		-	(21,483)
Share-based payments expense	18	(3,843,240)	(1,562,838)
Product development testing		(472,231)	(216,832)
Travel expenses		(746,826)	(499,418)
Other expenses	16	(1,343,413)	(1,168,884)
		<b>(13,724,114)</b>	<b>(8,713,118)</b>

LOSS			
Loss before income tax		(12,491,037)	(7,497,092)
Income tax expense	26	-	-
Loss for the year		(12,491,037)	(7,497,092)
Other comprehensive income / (loss)		-	-
<b>Total comprehensive loss for the year</b>		<b>(12,491,037)</b>	<b>(7,497,092)</b>

LOSS PER SHARE ATTRIBUTABLE TO THE OWNERS OF THE COMPANY (CENTS)			
Basic loss per share	27	(5.4)	(3.5)
Diluted loss per share	27	(5.4)	(3.5)

See accompanying notes to the consolidated financial statements.

# CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2024

	NOTE	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
<b>ASSETS</b>			
<b>CURRENT ASSETS</b>			
Cash and cash equivalents	3	3,554,485	5,164,663
Trade and other receivables	4	1,144,841	1,008,835
Other assets	5	522,866	382,304
		5,222,192	6,555,802
<b>NON-CURRENT ASSETS</b>			
Plant and equipment	6	521,194	316,804
Right of use asset	7	567,020	158,984
Intangible assets	8	5,967,549	5,115,101
Other assets	5	75,685	56,682
		7,131,448	5,647,571
<b>Total Assets</b>		<b>12,353,640</b>	<b>12,203,373</b>
<b>LIABILITIES</b>			
<b>CURRENT LIABILITIES</b>			
Trade and other payables	9	1,476,320	1,170,876
Lease liabilities	10	75,396	126,757
Provisions	11	170,551	107,203
		1,722,267	1,404,836
<b>NON-CURRENT LIABILITIES</b>			
Lease liabilities	10	491,624	30,724
Provisions	11	70,842	45,492
		562,466	76,216
<b>Total Liabilities</b>		<b>2,284,733</b>	<b>1,481,052</b>
<b>Net Assets</b>		<b>10,068,907</b>	<b>10,722,321</b>
<b>EQUITY</b>			
Share capital	12	41,021,685	32,360,091
Share-based payments reserve	13	8,592,859	6,039,351
Accumulated losses		(39,545,637)	(27,677,121)
<b>Total Equity</b>		<b>10,068,907</b>	<b>10,722,321</b>

See accompanying notes to the consolidated financial statements.

## CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

### FOR THE YEAR ENDED 30 JUNE 2024

	SHARE CAPITAL \$	SHARE-BASED PAYMENTS RESERVE \$	ACCUMULATED LOSSES \$	TOTAL \$
Balance at 1 July 2022	31,373,822	5,742,782	(20,660,029)	16,456,575
Loss for the year	-	-	(7,497,092)	(7,497,092)
Other comprehensive income	-	-	-	-
<b>Total comprehensive loss for the year</b>	<b>-</b>	<b>-</b>	<b>(7,497,092)</b>	<b>(7,497,092)</b>
Options exercised	200,000	-	-	200,000
Share based payments	786,269	776,569	-	1,562,838
Performance shares lapsed	-	(480,000)	480,000	-
<b>Balance at 30 June 2023</b>	<b>32,360,091</b>	<b>6,039,351</b>	<b>(27,677,121)</b>	<b>10,722,321</b>
Balance at 1 July 2023	32,360,091	6,039,351	(27,677,121)	10,722,321
Loss for the year	-	-	(12,491,037)	(12,491,037)
Other comprehensive income	-	-	-	-
<b>Total comprehensive loss for the year</b>	<b>-</b>	<b>-</b>	<b>(12,491,037)</b>	<b>(12,491,037)</b>
Share based payments	120,439	99,410	-	219,849
Performance rights issued	-	1,569,863	-	1,569,863
Options issued	-	2,053,528	-	2,053,528
Options exercised	561,875	(565,519)	565,519	561,875
Options expired	-	(582,798)	582,798	-
Ordinary shares issued	8,440,360	-	-	8,440,360
Share issue costs	(464,727)	-	-	(464,727)
Director loan repaid	-	(20,973)	39,723	18,750
<b>Balance at 30 June 2024</b>	<b>41,021,685</b>	<b>8,592,859</b>	<b>(39,545,637)</b>	<b>10,068,907</b>

See accompanying notes to the consolidated financial statements.

# CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 30 JUNE 2024

	NOTE	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Receipts from customers and others		1,097,072	1,041,054
Payments to suppliers, employees and others		(9,024,633)	(6,525,047)
Interest received		23,025	-
Interest paid		-	(12,777)
<b>Net cash (used in) operating activities</b>	29	<b>(7,904,536)</b>	<b>(5,453,878)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Patents and trademarks expenditure		(830,469)	(842,463)
Development expenditure		(408,877)	(379,573)
Purchase of plant and equipment		(256,504)	(62,690)
<b>Net cash (used in) investing activities</b>		<b>(1,495,850)</b>	<b>(1,284,726)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Options exercised		561,875	200,000
Ordinary shares issued		7,878,485	-
Share issue costs		(464,727)	-
Loan repayments		-	(42,897)
Director loan repaid		18,750	-
Lease payments		(189,675)	(115,719)
<b>Net cash from financing activities</b>		<b>7,804,708</b>	<b>41,384</b>
<b>Net (decrease) in cash and cash equivalents</b>		<b>(1,595,678)</b>	<b>(6,697,220)</b>
Effects of currency translation on cash		(14,500)	108,010
Cash and cash equivalents at beginning of year		5,164,663	11,753,873
<b>Cash and cash equivalents at end of year</b>	3	<b>3,554,485</b>	<b>5,164,663</b>

See accompanying notes to the consolidated financial statements.



These notes form an integral part of and should be read in conjunction with the accompanying financial report:

## 1. CORPORATE INFORMATION AND CONSOLIDATED STATEMENT OF COMPLIANCE

The consolidated financial report covers ClearVue Technologies Limited ("the Company") and its controlled entities ("the Group"). The Company is a Company limited by shares, incorporated and domiciled in Australia; whose shares are publicly traded on the Australian Stock Exchange. The address of its registered office and its principal place of business is Suite 9/365 Newcastle Street, West Perth, WA 6005, Australia.

The consolidated annual report for the year ended 30 June 2024 was authorised for issue, in accordance with a resolution of Directors, on 29 September 2024. The Directors have the power to amend and reissue the financial statements.

The consolidated annual report is a general-purpose financial report that have been prepared in accordance with the requirements of the Corporations Act 2001, Accounting Standards and other authoritative pronouncements of the Australian Accounting Standards Board. Compliance with Australian Accounting Standards results in full compliance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).

### **Nature of Operations**

The principal activities of the Group during the course of the year were research and development activities applied to the Company's world leading solar glass technology.

## 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES

The following is a summary of the material accounting policies adopted by the economic entity in the preparation of the consolidated annual report. The accounting policies have been consistently applied, unless otherwise stated.

### 2.1 Basis of preparation

Except for cash flow information, the consolidated annual report is prepared on an accruals basis and is based on historical costs. The consolidated annual report has been prepared under the assumption that the Group operates on a going concern basis. The financial statements have been presented in Australian dollars (AUD), which is the Group's functional and presentation currency.

### 2.2 Going concern

The Group incurred an operating loss after income tax for the year ended 30 June 2024 of \$12,491,037 (\$7,497,092 loss for 2023) and reported net cash outflows from operating activities of \$7,904,536 (\$5,453,878 outflows for 2023) and investing activities of \$1,495,850 cash outflow (\$1,284,726 outflow for 2023). As at 30 June 2023, the Group had available cash and cash equivalents of \$5,164,663 (\$5,164,663 at 30 June 2023). The Company has the ability to defer or reduce its operating expenditure.

During the period the Group established a \$30 million, 5-year At-Call Funding Facility with Alpha Investment Partners to support growth plans and progress towards commercialisation, as at 30 June 2024 the Group had a nominal \$28.275 million At-Call Funding Facility available.

On 8 July 2024 the Group used its At-Call Funding Facility with Alpha Investment Partners (see announcement 8 July 2024) to raise \$2,733,000 (before costs) by agreeing to a deemed issuance of 5,000,000 CPV fully paid ordinary shares to Alpha Investment Partners at an issue of \$0.5466 per share.

In assessing the appropriateness of the going concern assumption, the directors have considered the Group's successful history of capital raising, including the available At-Call Funding Facility and the ability to moderate expenditure.

This financial report has been prepared on a going concern basis which contemplates the continuity of normal business activities and the realisation of assets and settlement of liabilities in the ordinary course of business.

The continuing viability of the Group and its ability to continue as a going concern is dependent upon the Group being successful in its continuing efforts in development projects and accessing additional sources of funding to meet the commitments within one year from the date of signing the financial report.

In assessing the appropriateness of the going concern assumption, the directors have considered the Group's successful history of capital raising, its discussions with potential capital investors and the ability to moderate expenditure.

This financial report has been prepared on a going concern basis which contemplates the continuity of normal business activities and the realisation of assets and settlement of liabilities in the ordinary course of business.

## 2.3 Cash and cash equivalents

Cash and cash equivalents include cash on hand, deposits held on call with banks and other short-term highly liquid investments with original maturities of three months or less.

## 2.4 Plant and equipment

Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation is computed on a straight line basis over the estimated useful lives of the assets as follows:

Furniture	10%-15%
Office equipment	28%-33.3%
Machinery	13%-15%

The carrying values of plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable. The residual value, useful life and depreciation method are reviewed at the end of each financial year to ensure that the amount, method and period of depreciation are consistent with previous estimates and the expected pattern of consumption of the future economic benefits embodied in the items of plant and equipment.

An item of plant and equipment is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on derecognition of the asset is included in profit or loss in the year the asset is derecognised.

## 2.5 Intangible assets

### Patents and trademarks

Patents and trademarks costs are capitalised in the period in which they are incurred and amortised over their useful lives. Patents and trademark are amortised over 20 years from the date of purchase.

## Research and development

Development costs are capitalised when it is probable that the project will be a success considering its commercial and technical feasibility; the consolidated entity is able to use or sell the asset; the consolidated entity has sufficient resources; and intent to complete the development and its costs can be measured reliably. Capitalised development costs are amortised over the period of their expected useful life, when the asset is determined available for use. The useful life, when available for use has been determined to be 20 years based on the expected viability of the product. Patents costs that relate to projects that are in the development phase are capitalised.

Research and development grants receivable are matched to their classification of expenditure. In the periods where research costs are expensed, the related research and development grant is reported in the Consolidated Statement of Profit or Loss and Other Comprehensive Income as other income. In periods where the Group incurs Development Costs, the related Research and Development grant is recognised in the Consolidated Statement of Profit or Loss and Other Comprehensive Income.

The carrying value of development expenditure, intangible assets and intellectual property is tested for impairment annually when the asset is not yet available for use or more frequently when an indication of impairment arises during the reporting period.

## 2.6 Trade and other payables

These amounts represent liabilities for goods and services provided to the entity prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

## 2.7 Provisions

Provisions are recognised when the entity has a legal or constructive obligation resulting from past events, for which it is probable that there will be an outflow of economic benefits and that outflow can be reliably measured. Provisions are measured using the best estimate available of the amounts required to settle the obligation at the end of the reporting period.

## 2.8 Financial instruments

### **Recognition, initial measurement and derecognition**

Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted by transactions costs, except for those carried at fair value through profit or loss, which are measured initially at fair value. Subsequent measurement of financial assets and financial liabilities are described below.

Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and all substantial risks and rewards are transferred. A financial liability is derecognised when it is extinguished, discharged, cancelled or expires.

### **Classification and subsequent measurement of financial assets**

Except for those trade receivables that do not contain a significant financing component and are measured at the transaction price in accordance with AASB 15, all financial assets are initially measured at fair value adjusted for transaction costs (where applicable).

For the purpose of subsequent measurement, financial assets other than those designated and effective as hedging instruments are classified into the following categories upon initial recognition:

- Amortised cost
- Fair value through profit or loss (FVPL)
- Equity instruments at fair value through other comprehensive income (FVOCI)
- Debt instruments at fair value through other comprehensive income (FVOCI)

All income and expenses relating to financial assets that are recognised in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables which is presented within other expenses.

Classifications are determined by both:

- The entities business model for managing the financial asset
- The contractual cash flow characteristics of the financial assets

All income and expenses relating to financial assets that are recognised in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables, which is presented within other expenses.

### **Financial assets at amortised cost**

Financial assets are measured at amortised cost if the assets meet the following conditions (and are not designated as FVPL):

- They are held within a business model whose objective is to hold the financial assets and collect its contractual cash flows
- The contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding

After initial recognition, these are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. The Group's cash and cash equivalents, trade and most other receivables fall into this category of financial instruments.

There are no FVPL and FVOCI instruments for the group.

### **Impairment of financial assets**

AASB 9's impairment requirements use more forward-looking information to recognise expected credit losses – the 'expected credit losses (ECL) model'. Instruments within the scope of the new requirements included loans and other debt-type financial assets measured at amortised cost and FVOCI, trade receivables, contract assets recognised and measured under AASB 15 and loan commitments and some financial guarantee contracts (for the issuer) that are not measured at fair value through profit or loss.

The Group considers a broader range of information when assessing credit risk and measuring expected credit losses, including past events, current conditions, reasonable and supportable forecasts that affect the expected collectability of the future cash flows of the instrument.

In applying this forward-looking approach, a distinction is made between:

- Financial instruments that have not deteriorated significantly in credit quality since initial recognition or that have low credit risk ('Stage 1') and
- Financial instruments that have deteriorated significantly in credit quality since initial recognition and whose credit risk is not low ('Stage 2').

'Stage 3' would cover financial assets that have objective evidence of impairment at the reporting date. '12-month expected credit losses' are recognised for the first category while 'lifetime expected credit losses' are recognised for the second category. Measurement of the expected credit losses is determined by a probability-weighted estimate of credit losses over the expected life of the financial instrument.

## 2.8 Financial instruments (continued)

### **Trade and other receivables and contract assets**

The Group makes use of a simplified approach in accounting for trade and other receivables as well as contract assets and records the loss allowance at the amount equal to the expected lifetime credit losses. In using this practical expedient, the Group uses its historical experience, external indicators and forward-looking information to calculate the expected credit losses using a provision matrix.

### **Classification and measurement of financial liabilities**

The Group's financial liabilities include trade and other payables.

Financial liabilities are initially measured at fair value, and, where applicable, adjusted for transaction costs unless the Group designated a financial liability at fair value through profit or loss. Subsequently, financial liabilities are measured at amortised cost using the effective interest method except for derivatives and financial liabilities designated at FVPL, which are carried subsequently at fair value with gains or losses recognised in profit or loss (other than derivative financial instruments that are designated and effective as hedging instruments).

All interest-related charges and, if applicable, changes in an instrument's fair value that are reported in profit or loss are included within finance costs or finance income.

## 2.9 Impairment of non-financial assets

At each reporting date, the directors review the carrying values of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the assets fair value less costs to sell and value in use, is compared to the asset's carrying value. Any excess of the assets carrying value over its recoverable amount is recognised in profit or loss.

## 2.10 Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the entity's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the entity's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

## 2.11 Issued capital

Ordinary shares are classified as equity. Issued and paid up capital is recognised at the fair value of the consideration received by the Company. Any transaction costs arising on the issue of ordinary shares are recognised directly in equity as a reduction of the share proceeds received.

### **Basic loss per share**

Basic loss per share is determined by dividing the operating profit/(loss) after income tax attributable to members of ClearVue Technologies Limited by the weighted average number of ordinary shares outstanding during the financial year.

### **Diluted loss per share**

Diluted loss per share adjusts the amounts used in the determination of basic loss per share by taking into account unpaid amounts on ordinary shares and any reduction in loss per share that will probably arise from the exercise of options outstanding during the financial year.



## 2.12 Revenue and other income recognition

### **Revenue from contracts with customers**

The company has generated income from the sale of integrated glass unit windows. Revenue from the sale of the goods is recognised when control has passed to the customer.

Control is considered passed when:

- Physical possession and inventory risk is transferred
- Payment for the goods has been received
- The customer has no practical ability to reject the product where it is within contractual specified limits.

### **Grant income**

Grant income is recognised in the income statement, when it is probable that the entity will receive the economic benefits of the grant and the amount can be reliably measured. If the grant has conditions attached which must be satisfied before the entity is eligible to receive the grant, the recognition of the income will be deferred until those conditions are satisfied.

Where the entity incurs an obligation to deliver economic value back to the grant contributor, the transaction is considered a reciprocal transaction and the income is recognised as a liability in the Consolidated Statement of financial position until the required service has been completed, otherwise the income is recognised on receipt.

Government grants are recognised when it is received or when the right to receive payment is established.

### **Interest**

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

### **Other income**

Other revenue is recognised when it is received or when the right to receive payment is established.

## 2.13 Employee benefits

### **Short-term employee benefits**

Short-term employee benefits are benefits, other than termination benefits, that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. Examples of such benefits include wages and salaries, non-monetary benefits and accumulating sick leave. Short-term employee benefits are measured at the undiscounted amounts expected to be paid when the liabilities are settled.

### **Other long-term employee benefits**

The Group's liabilities for annual leave and long service leave are included in other long term benefits as they are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. They are measured at the present value of the expected future payments to be made to employees. The expected future payments incorporate anticipated future wage and salary levels, experience of employee departures and periods of service, and are discounted at rates determined by reference to market yields at the end of the reporting period on high quality corporate bonds that have maturity dates that approximate the timing of the estimated future cash outflows. Any re-measurements arising from experience adjustments and changes in assumptions are recognised in profit or loss in the periods in which the changes occur.

### **Defined contribution superannuation expense**

Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred.

## 2.14 Share-based payments

Equity-settled and cash-settled share-based compensation benefits are provided to employees.

Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services. Cash-settled transactions are awards of cash for the exchange of services, where the amount of cash is determined by reference to the share price.

The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using either the Binomial or Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the entity receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions.

The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying either the Binomial or Black-Scholes option pricing model, taking into consideration the terms and conditions on which the award was granted. The cumulative charge to profit or loss until settlement of the liability is calculated as follows:

- During the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period.
- From the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date.

All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the cash paid to settle the liability.

Market conditions are taken into consideration in determining fair value. Therefore, any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied.

If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification.

If the non-vesting condition is within the control of the entity or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the entity or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited.

If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.

## 2.15 Income tax

The charge for current income tax expenses is based on the profit for the year adjusted for any non-assessable or disallowed items. It is calculated using tax rates that have been enacted or are substantively enacted by the end of each financial year.

Deferred tax is accounted for using the balance sheet liability method in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. No deferred income tax will be recognised from the initial recognition of an asset or liability, excluding business combination, where there is no effect on accounting or taxable profit or loss.

Deferred tax is calculated at the tax rates that are expected to apply to the period when the asset is realised or liability is settled. Deferred tax is credited in profit and loss except where it relates to items that may be credited directly to equity, in which case the deferred tax is adjusted directly against equity.

Deferred income tax assets are recognised to the extent that it is probable that future tax profits will be available against which deductible temporary differences can be utilised.

The amount of benefits brought to account or which may be realised in the future is based on the assumption that no adverse change will occur in income tax legislation and the anticipation that the economic entity will derive sufficient future assessable income to enable the benefit to be realised and comply with the conditions of deductibility imposed by the law.

## 2.16 Goods and Service Tax (GST)

Transactions are recognised net of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO).

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the Consolidated Statement of financial position.

## 2.17 Critical accounting estimates and judgements

When preparing the financial report, management undertakes a number of judgements, estimates and assumptions about the recognition and measurement of assets, liabilities, income and expenses.

The management is of the opinion that there are no significant judgments made (other than those involving estimates) in applying accounting policies that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

Information about estimates and assumptions that have the most significant effect on recognition and measurement of assets, liabilities, income and expenses is provided below. Actual results may be substantially different.

### **Share based payments**

The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by an external valuer using a Black-Scholes model, using the assumptions detailed in Note 13.

### **Impairment of intangible assets**

Intangible assets are reviewed for impairment whenever there is an indication that these assets may be impaired. This includes any capitalised internally developed software that is not yet complete is not amortised. The Group considers the guidance of AASB 136 in assessing whether there is any indication that an item of the above assets may be impaired. This assessment requires management's judgement. If any such indication exists, the recoverable amount of the assets is estimated to ascertain the amount of impairment loss. The recoverable amount is defined as the higher of the fair value less cost to sell and value in use.

The Group reviews the appropriateness of the useful lives and residual values of intangible assets at the end of each reporting period. Changes in the expected level of usage and technological developments could impact the economic useful lives and residual values of these assets. Where there is a material change in the useful lives and residual values of intangible assets, such a change may impact the future amortisation charge in the financial year in which the change arises.

### **Deferred tax**

The Company expects to have carried forward tax losses which have not been recognised as deferred tax assets as it is not considered sufficiently probable that these losses will be recouped by means of future profits taxable in the relevant jurisdictions.

## 2.18 Principles of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of ClearVue Technologies Limited ('Company') as at 30 June 2024 and the results of all subsidiaries for the year then ended. The Group and its subsidiaries together are referred to in these financial statements as the 'consolidated entity'.

Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de-consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent.

## 2.19 Operating segments

Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Board of Directors. They are responsible for the allocation of resources to operating segments and assessing their performance.

## 2.20 Leases

The Group considers whether a contract is, or contains a lease. A lease is defined as 'a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration'. To apply this definition the Group assesses whether the contract meets three key evaluations which are whether:

- The contract contains an identified asset, which is either explicitly identified in the contract or implicitly specified by being identified at the time the asset is made available to the Group
- The Group has the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use, considering its rights within the defined scope of the contract
- The Group has the right to direct the use of the identified asset throughout the period of use. The Group assess whether it has the right to direct 'how and for what purpose' the asset is used throughout the period of use.

### **Measurement and recognition of leases**

At lease commencement date, the Group recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement date (net of any incentives received).

The Group depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term.

The Group also assesses the right-of-use asset for impairment when such indicators exist. At the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the Group's incremental borrowing rate.

Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised.

Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is remeasured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments.

## 2.21 New or amended accounting standards and interpretations not yet effective and not early adopted by the group

At the date of authorisation of these financial statements, several new, but not yet effective, Standards and amendments to existing Standards, and Interpretations have been published by the IASB. None of these Standards or amendments to existing Standards have been adopted early by the Group.

Management anticipates that all relevant pronouncements will be adopted for the first period beginning on or after the effective date of the pronouncement. New Standards, amendments and Interpretations not adopted in the current year have not been disclosed as they are not expected to have a material impact on the Group's financial statements.

There are expected to be material impacts from AASB 18 Presentation and Disclosure in Financial Statements: AASB 18 replaces AASB 101 as the standard describing the primary financial statements and sets out requirements for the presentation and disclosure information in AASB-compliant financial statements. The amendments are effective for annual reporting periods beginning on or after 1 January 2027.



## 3. CASH AND CASH EQUIVALENTS

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Cash at bank	3,554,485	5,164,663

## 4. TRADE AND OTHER RECEIVABLES

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Trade receivables	40,558	73,371
R&D rebate receivable	1,104,283	935,464
	1,144,841	1,008,835

## 5. OTHER ASSETS

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
<b>CURRENT</b>		
Goods and service tax (GST)	100,769	39,715
Prepayments	192,809	316,283
Inventory	25,868	25,868
Other	203,420	438
	522,866	382,304
<b>NON-CURRENT</b>		
Deposits	75,685	56,682



## 6. PLANT AND EQUIPMENT

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Cost	755,812	499,307
Less accumulated depreciation	(234,618)	(182,503)
<b>Carrying amount</b>	<b>521,194</b>	<b>316,804</b>

COST		
Balance at 1 July	499,307	436,618
Additions	256,505	62,689
<b>Balance at 30 June</b>	<b>755,812</b>	<b>499,307</b>

ACCUMULATED DEPRECIATION		
Balance at 1 July	182,503	154,101
Depreciation for the year	52,115	28,402
<b>Balance at 30 June</b>	<b>234,618</b>	<b>182,503</b>
<b>Carrying amount at 30 June</b>	<b>521,194</b>	<b>316,804</b>

## 7. RIGHT-OF-USE ASSET

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Cost	1,033,552	434,332
Less accumulated amortisation	(466,532)	(275,348)
<b>Carrying amount</b>	<b>567,020</b>	<b>158,984</b>

COST		
Balance at 1 July	434,332	334,980
Additions	599,220	99,352
<b>Balance at 30 June</b>	<b>1,033,552</b>	<b>434,332</b>

ACCUMULATED AMORTISATION		
Balance at 1 July	275,348	162,760
Depreciation for the period	191,184	112,588
<b>Balance at 30 June</b>	<b>466,532</b>	<b>275,348</b>
<b>Carrying amount at 30 June</b>	<b>567,020</b>	<b>158,984</b>

## 8. INTANGIBLE ASSETS

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Patents and trademarks	3,378,822	2,795,872
Development asset	2,588,727	2,319,229
	<b>5,967,549</b>	<b>5,115,101</b>

## PATENTS AND TRADEMARKS

Cost	4,304,500	3,474,030
Less accumulated amortisation	(925,678)	(678,158)
<b>Carrying amount</b>	<b>3,378,822</b>	<b>2,795,872</b>

## COST

Balance at 1 July	3,474,030	2,631,567
Additions <sup>1</sup>	830,470	842,463
<b>Balance at 30 June</b>	<b>4,304,500</b>	<b>3,474,030</b>

## ACCUMULATED AMORTISATION

Balance at 1 July	678,158	534,646
Amortisation for the year	247,520	143,512
<b>Balance at 30 June</b>	<b>925,678</b>	<b>678,158</b>

## DEVELOPMENT ASSET

Cost	2,787,573	2,378,696
Less accumulated amortisation	(198,846)	(59,467)
<b>Carrying amount</b>	<b>2,588,727</b>	<b>2,319,229</b>

## COST

Balance at 1 July	2,378,696	1,999,122
Additions	408,877	379,574
<b>Balance at 30 June</b>	<b>2,787,573</b>	<b>2,378,696</b>

## ACCUMULATED AMORTISATION

Balance at 1 July	59,467	–
Amortisation for the year	139,379	59,467
<b>Balance at 30 June</b>	<b>198,846</b>	<b>59,467</b>
<b>Carrying amount at 30 June</b>	<b>2,588,727</b>	<b>2,319,229</b>
<b>Net carrying amount at 30 June</b>	<b>5,967,549</b>	<b>5,115,101</b>

Total research and development expenditure incurred in the profit and loss for the year amounted to \$2,274,554 (2023: 1,789,911).

Intangible assets are stated at cost. The useful life of these patents and trademarks is estimated to be finite. No impairment losses were recognised during the financial year (2023: nil).

## 9. TRADE AND OTHER PAYABLES

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Trade payables	683,147	559,950
Prepaid revenue	167,532	78,636
Unacquitted Grant	300,000	300,000
Other payables	115,125	115,404
Accruals	210,516	116,886
	<b>1,476,320</b>	<b>1,170,876</b>

## 10. LEASE LIABILITIES

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Current	75,396	126,757
Non-Current	491,624	30,724

The Group has leases for the office and photocopier. The lease liabilities are secured by the related underlying assets.

Future minimum lease payments at 30 June 2023 were as follows:

	WITHIN 1 YEAR \$	1-5 YEARS \$	AFTER 5 YEARS \$	TOTAL \$
Lease payments	100,246	440,014	120,506	660,766
Finance charges	24,850	65,612	3,284	93,746
Net present value	75,396	374,402	117,222	567,020

*Lease payments not recognised as a liability.*

Certain variable lease payments are not permitted to be recognised as lease liabilities and are expensed as incurred. The expense relating to payments not recognised as lease liability is as follows:

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Depreciation expense (Note 7)	158,984	112,588
Interest expense	(23,025)	12,777
Variable lease payments	62,225	42,086

Variable lease payments are expensed on the basis that they are not recognised as a lease liability include excess use charges on office equipment. Variable payment terms are used for a variety of reasons, including minimising costs for equipment with infrequent use. Variable lease payments are expensed in the period they are incurred.



## 11. PROVISIONS

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
<b>CURRENT</b>		
Annual leave provision	170,551	107,203
Long service leave provision	–	–
	<b>170,551</b>	<b>107,203</b>
<b>NON-CURRENT</b>		
Long service leave provision	70,842	45,492
	<b>70,842</b>	<b>45,492</b>

## 12. SHARE CAPITAL

	30 JUN 2024 NO. OF SHARES	30 JUN 2023 NO. OF SHARES	30 JUN 2024 \$	30 JUN 2023 \$
<b>SHARE ISSUED AND FULLY PAID</b>				
Balance at 1 July	217,171,757	212,040,344	32,360,091	31,373,823
Shares issued	12,307,000	–	8,440,360	–
Share based payments	10,254,717	4,131,413	120,439	786,268
Options exercised	2,925,000	1,000,000	565,522	200,000
Share issue costs	–	–	(464,727)	–
<b>Balance at 30 June</b>	<b>242,658,474</b>	<b>217,171,757</b>	<b>41,021,685</b>	<b>32,360,091</b>

The share capital of the Company consists only of fully paid ordinary shares; the shares do not have a par value. All shares are equally eligible to receive dividends and the repayment of capital and represent one vote at the shareholders' meeting of the Company.

### 13. SHARE-BASED PAYMENTS RESERVE

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Opening balance	6,039,351	5,742,782
Performance Rights Issued	1,569,863	
Options Issued	2,053,528	776,569
Options Exercised	-565,522	
Options expired	-582,798	-480,000
Share based payment	99,410	
Director Loan repaid	-20,973	
	<b>8,582,859</b>	<b>6,039,351</b>

1 The share plan arises on the grant of loan for a term of 10 years to Directors and related parties for the purchase of the Company's ordinary shares under the ClearVue Loan Funded Share Plan in 2017. Amounts are transferred out of the reserve and into share capital when the loans are settled.

	NO. OF OPTIONS	NO. OF PERFORMANCE RIGHTS	NO. OF PERFORMANCE SHARES	\$
<b>MOVEMENTS IN SHARE BASED PAYMENT RESERVE</b>				
Balance at 1 July 2022	16,694,867	10,000,000	3,000,000	5,742,782
Options issued	11,500,000	-	-	532,559
Options exercised	(1,000,000)	-	-	-
Options expired	(8,144,867)	-	-	244,010
Performance shares cancelled	-	-	(3,000,000)	(480,000)
<b>Balance at 30 June 2023</b>	<b>19,050,000</b>	<b>10,000,000</b>	<b>-</b>	<b>6,039,351</b>

	NO. OF OPTIONS	NO. OF PERFORMANCE RIGHTS	\$
<b>MOVEMENTS IN SHARE BASED PAYMENT RESERVE</b>			
Balance at 1 July 2023	19,050,000	10,000,000	6,039,351
Options issued	10,602,262	-	2,053,528
Options exercised	(2,925,000)	-	(565,522)
Options expired	(5,000,000)	-	(582,798)
Options vested	-	-	99,410
Director loan repaid	-	-	(20,973)
Performance rights issued	-	5,000,000	1,569,863
<b>Balance at 30 June 2024</b>	<b>21,727,262</b>	<b>15,000,000</b>	<b>8,592,859</b>

## 13. SHARE-BASED PAYMENTS RESERVE (CONTINUED)

CLASS	NUMBER	GRANT DATE	EXPIRY DATE	VESTING CONDITION
CPVAS	93,333	19/06/2024	19/06/2026	No vesting conditions
CPVAR	5,508,929	10/04/2024, 26/03/2024 and 12/03/2024	12/03/2026	All options require the holder to remain continuously employed or engaged with the Group at all times to 12 March 2026.
CPVAO <sup>3</sup>	1,000,000	30/10/2023	30/10/2027	Options vest on the condition the share price of the Company reaches \$0.50 and maintains a VWAP of \$0.50 for at least 14 days within and prior to the expiry
CPVAP <sup>2</sup>	2,000,000	13/12/2023	13/12/2026	All options require holder to remain continuously employed or engaged with the Group at all times to 13 December 2026
CPVAQ <sup>2</sup>	2,000,000	13/12/2023	13/12/2026	All options require holder to remain continuously employed or engaged with the Group at all times to 13 December 2026
CPVAK	2,625,000	20/06/2023	30/11/2024	No vesting conditions
CPVAL	2,500,000	20/06/2023	30/11/2025	No vesting conditions
CPVAM	3,000,000	20/06/2023	30/11/2026	No vesting conditions
CPVAN	3,000,000	23/05/2023	12/07/2027	The options comprise vesting milestones of 500,000 tranche 1 options (VWAP of \$1.00 per share for at least 30 days), 500,000 tranche 2 options (introducing and procuring a strategic alliance), 500,000 tranche 3 options (VWAP of \$1.50 per share for at least 30 days), 500,000 tranche 4 options (securing a commercial deployment) and 1,000,000 tranche 5 options (commence up-listing of its OTCQB listing onto the NASDAQ).
<b>TOTAL</b>	<b>21,727,262</b>			





### 13. SHARE-BASED PAYMENTS RESERVE (CONTINUED)

The following table illustrates the number and weighted average exercise prices of and movements in share options issued during the year:

	2024		2023	
	NUMBER	WEIGHTED AVERAGE EXERCISE PRICE \$	NUMBER	WEIGHTED AVERAGE EXERCISE PRICE \$
Outstanding at the beginning of year	19,050,000	0.195	16,694,867	0.195
Granted during the year	10,602,262	0.68	11,500,000	0.36
Exercised during the year	(2,925,000)	0.19	(1,000,000)	0.20
Expired during the year	(5,000,000)	0.52	(8,144,867)	0.20
<b>Outstanding at the end of year</b>	<b>21,727,262</b>	<b>0.52</b>	<b>19,050,000</b>	<b>0.378</b>
<b>Exercisable at the end of year</b>	<b>14,727,262</b>	<b>0.51</b>	<b>13,050,000</b>	<b>0.41</b>

The fair value of the equity-settled share options listed below is estimated as at the date of grant using the Black-scholes and Monte Carlo models taking into account the terms and conditions upon which the options were granted.

	CPV	CPVAL	CPVAM	CPVAN	CPVAO	CPVAP	CPVAQ
Dividend yield (%)	–	–	–	–	–	–	–
Expected volatility (%)	93.39	93.39	93.39	93.39	90.00	93.39	93.39
Risk-free interest rate (%)	5.0	5.0	5.0	5.0	4.0	5.0	5.0
Expected life of option (years)	1.92	1.45	2.45	3.45	4.00	3.00	3.00
Exercise price (cents)	75	30	40	50	0	50	100
Grant date share price (cents)	46	17	17	17	31	47.5	47.5
Number of options	1,500,000	2,500,000	3,000,000	3,000,000	1,000,000	2,000,000	2,000,000
Model used	Black Scholes	Black Scholes	Black Scholes	Black Scholes	Monte Carlo	Black Scholes	Black Scholes

The expected life of the options is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome. No other features of options granted were incorporated into the measurement of fair value.



### 13. SHARE-BASED PAYMENTS RESERVE (CONTINUED)

The conversion of the performance rights is dependent on the following:

#### a. Class A Performance Rights

- i) In the event that the aggregate of the value of the ClearVue (Orders and the ClearVue Payments is equal to or greater than \$2,000,000 within a period of 24 months commencing on the date of issue of the Performance Rights (Issue Date) (Class A Milestone 1), each Class A Performance Right will vest and be convertible into one Share; or
- ii) in the event that Class A Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$7,000,000 within a period of 36 months from the Issue Date (Class A Milestone 2), each Class A Performance Right will vest and be convertible into one Share; or
- iii) in the event that neither Class A Milestone 1 or Class A Milestone 2 is satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Issue Date, each Class A Performance Right will vest and be convertible into one Share.

#### b. Class B Performance Rights

- i) In the event that the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$5,000,000 within a period of 24 to 36 months from the Issue Date (Class B Milestone 1), each Class B Performance Right will vest and be convertible into one Share; or
- ii) in the event that Class B Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$7,000,000 within a period of 36 months from the Issue Date (Class B Milestone 2), each Class B Performance Right will vest and be convertible into one Share; or
- iii) in the event that neither Class B Milestone 1 or Class B Milestone 2 is satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Issue Date, each Class B Performance Right will vest and be convertible into one Share.

#### c. Class C Performance Rights

- i) In the event that the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$10,000,000 within a period of 36 to 48 months from the Issue Date (Class C Milestone 1), each Class C Performance Right will vest and be convertible into one Share; or
- ii) In the event that Class C Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Issue Date, each Class C Performance Right will vest and be convertible into one Share.

#### d. Class D Performance Rights

- i) In the event that the participant assisting the company completes the development and testing of vision and spandrel glass to achieve an A2 SO D1 fire rating confirmed by an independent third party testing, with such testing party approved by the company and certified to the EN13501.1 standard before the expiry date, each class D performance right will vest and be convertible into a share.

#### e. Class E Performance Rights

- i) In the event that the participant introduces an equity investor to the company where the equity investment transaction is concluded and / or the participant has carriage of concluding an equity investment transaction before the expiry date, each of the class E performance rights will vest and be convertible into a share.

#### f. Class F Performance Rights

- i) (A) In the event that the participant introduces an equity investor to the company where the equity investment transaction is concluded and / or the participant has carriage of concluding an equity investment transaction before the expiry date, each of the class E performance rights will vest and be convertible into a share.

### 13. SHARE-BASED PAYMENTS RESERVE (CONTINUED)

#### g. Class G Performance Rights

- i) In the event that the participant assists the company to complete an up-listing of its OTCQB US or ASX listing into the main US board of the NASDAQ or the NYSE before the expiry date or have commenced at least 3 months before the expiry date and such up-listing is completed within a further 6 months after the end of the expiry date, each of the class G performance rights will vest and be convertible into a share.

#### h. Class H Performance Rights

- i) In the event the share price for the ordinary shares of the company reaches \$0.50 and maintains a volume weighted average of \$0.50 per ordinary share for at least 14 days with and before the expiry date, each of the class H performance rights will vest and be convertible into a share.

#### i. Class I Performance Rights

- i) In the event that the company receives revenue of AUD\$1,500,000 from the sale of its own products (incorporating the ClearVue technology) during a twelve month period before the expiry date, each of the class E performance rights will vest and be convertible into a share.

#### j. Class J Performance Rights

- i) In the event that the company receives revenue of AUD\$1,500,000 from the sale of its own products (incorporating the ClearVue technology) during a twelve month period before the expiry date, each of the class E performance rights will vest and be convertible into a share.

The fair value of the performance rights issued during the year is estimated as at the date of grant using the Black-scholes and Monte Carlo models taking into account the terms and conditions upon which the rights were granted.

	CLASS D	CLASS E	CLASS F	CLASS G	CLASS H	CLASS I	CLASS J
Method	Black Scholes	Black Scholes	Black Scholes	Black Scholes	Monte Carlo	Black Scholes	Black Scholes
Grant date	21/9/23	9/10/23	9/10/23	9/10/23	10/10/23	10/10/23	10/10/23
Expiry date	30/10/27	30/10/27	30/10/27	30/10/27	30/10/27	30/10/27	30/10/27
Grant date share price (cents)	33.5	31	31	31	32	32	32
Risk free interest rate (%)	4	4	4	4	4	4	4
Volatility (%)	90	90	90	90	90	90	90
Fair value per security (cents)	33.5	31	31	31	26.97	32	32
Number of Performance Rights	1,000,000	500,000	500,000	1,000,000	500,000	500,000	1,000,000

### 14. OTHER INCOME

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Government grants	54,587	53,273
Exchange gain on foreign currency bank accounts	–	108,010
Research and development tax rebate	1,104,284	935,466
Interest received	34,395	55,967
	<b>1,193,266</b>	<b>1,152,716</b>

Government grants received from the Department of Industry, Innovation and Science in relation to the Commercial Research Centre.

### 15. FINANCE COSTS

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Interest expenses	(23,025)	12,777

## 16. OTHER EXPENSES

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Advertising and promotion	400,027	255,264
Freight and Courier fees	146,800	165,277
Insurance expense	117,927	108,121
Listing fees	328,626	132,334
Office expenses	89,397	110,079
Rental expenses	72,933	64,544
Staff recruitment	13,257	98,841
General expense	174,446	234,424
	<b>1,343,413</b>	<b>1,168,884</b>

## 17. AUDITOR'S REMUNERATION

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Audit / review of the financial report	<b>91,678</b>	<b>65,785</b>

## 18. SHARE-BASED PAYMENTS EXPENSE

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Shares issued to employees	–	760,000
Shares issued to consultants	120,439	26,269
Options issued to consultants	263,101	497,396
Performance rights issued	1,569,863	–
Options issued to Directors	1,490,943	
Options issued to employees	398,894	24,570
	<b>3,843,240</b>	<b>1,562,838</b>

## 19. RELATED PARTY TRANSACTIONS

### Key management personnel

The aggregate compensation made to directors and key management personnel of the Group is set out below.

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Short-term employee benefits	2,121,951	1,105,700
Post-employment benefits	146,351	78,388
Long-term employee benefits	–	(83,580)
Share-based payments	3,459,700	795,163
Directors fees from Gerd Hoenicke	60,000	10,000
Directors fees from Charles Mowrey	60,172	10,000
Directors fees From Victor Rosenberg	86,000	–
Directors fees from Jamie Lyford	25,000	–
Consulting fees from John Downes	–	21,331
Directors fees from John Downes	–	44,429
Directors fees from Steinepreis Paganin <sup>1</sup>	–	28,000
	5,959,174	2,009,431

### Transactions with related parties

During the financial year, the following payments were made to director-related entities:

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Legal services from Steinepreis Paganin	–	30,078
Company secretarial services from Ventnor Capital Pty Ltd	–	63,400
Consultancy services from Luminate Pty Ltd <sup>1</sup>	227,050	70,000

1 Director-related entity of Mr Rosenberg consultancy services have been included in short term employee benefits in the remuneration report.

### Receivable from and payable to related parties

All transactions were made on normal commercial terms and conditions and at market rates.

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Trade payable to Ventnor Capital Pty Ltd <sup>1</sup>	–	5,500
Accrual to Mr Deil	–	35,980
Accrual to Gerd Hoenicke	40,000	10,000
Accrual to Charles Mowrey	–	10,000
Accrual to Luminate Pty Ltd <sup>5</sup>	10,000	10,000
Share plan reserve to Mr V Rosenberg <sup>1</sup>	150,000	150,000
Share plan reserve to Mr S Rosenberg <sup>2,4</sup>	–	18,750
Share plan reserve to Mr I Rosenberg <sup>2,4</sup>	18,750	18,750
Share plan reserve to Mr Lyford <sup>3</sup>	292,500	292,500

1 For the purchase of 1,000,000 shares at an issue price of \$0.15

2 For the purchase of 125,000 shares at an issue price of \$0.15

3 For the purchase of 1,950,000 shares at an issue price of \$0.15

4 Former key management personnel, further details provided on page 15

5 Director related entity of Mr Rosenberg



## 20. CONTINGENT ASSETS & LIABILITIES

There were no contingent assets or liabilities as at 30 June 2024 (2023: nil).

## 21. EVENTS SUBSEQUENT TO THE END OF THE REPORTING PERIOD

On the 8 July 2024 the "At the Market" facility exercised 5,000,000 shares for a gross equity raise of \$2,733,000 (\$2,596,350 after fees).

On 25 July 2024 125,000 fully paid ordinary shares were issued on the conversion of options at \$0.30 each.

No other matters or circumstances have arisen since 30 June 2024 that has significantly affected, or may significantly affect the Company's operations, the results of those operations, or the Company's state of affairs in future financial years.

## 22. DIVIDENDS

No dividend has been declared or paid out in the financial year ended 30 June 2024 (2023: nil). The Directors do not recommend the declaration of a dividend.

## 23. OPERATING SEGMENTS

Management has determined the operating segments based on reports reviewed by the Board of Directors for making strategic decisions. The current Board of Directors monitors the business based on operational and geographic factors and have determined that there is only one relevant business segment being ClearVue Technologies Limited and its controlled entities. The Group is domiciled in Australia and all revenue and expenditure is generated from Australia, and all assets are located in Australia.

## 24. CONSOLIDATED ENTITY

The consolidated financial statements incorporate the assets, liabilities and results of the following wholly-owned subsidiaries in accordance with the accounting policy in Note 2.

NAME OF ENTITY	TYPE OF ENTITY	COUNTRY OF INCORPORATION	OWNERSHIP 30 JUNE 2024	OWNERSHIP 30 JUNE 2023
ClearVue Technologies Limited	Body Corporate	Australia	N/A	N/A
ClearVue International Pty Ltd	Body Corporate	Australia	100%	100%
ClearVue USA Inc	Body Corporate	United States of America	100%	100%
ClearVue (Asia) Pte Ltd	Body Corporate	Singapore	100%	100%
ClearVue Europe BV	Body Corporate	Netherlands	100%	100%
ClearVue Europe Holdings BV	Body Corporate	Netherlands	100%	100%

## 25. PARENT ENTITY INFORMATION

	30 JUN 2024 \$	30 JUN 2023 \$
<b>CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME</b>		
Loss after income tax	(11,973,583)	(11,973,583)
Other comprehensive income	–	–
<b>Total comprehensive income</b>	<b>(11,973,583)</b>	<b>(11,973,583)</b>
<b>CONSOLIDATED STATEMENT OF FINANCIAL POSITION</b>		
<b>Total current assets</b>	<b>6,121,609</b>	<b>6,560,909</b>
<b>Total assets</b>	<b>12,189,329</b>	<b>12,208,480</b>
<b>Total current liabilities</b>	<b>1,524,022</b>	<b>1,404,836</b>
<b>Total liabilities</b>	<b>1,594,863</b>	<b>1,481,052</b>
Share capital	40,456,163	32,360,091
Share based payments reserve	8,582,863	6,039,352
Accumulated losses	(38,454,560)	(27,672,015)
	<b>10,594,466</b>	<b>10,727,428</b>

**Guarantees**

The parent entity had no guarantees that were entered in relation to the debts of its subsidiaries.

**Contingent liabilities**

The parent entity had no contingent liabilities as at 30 June 2024 and 30 June 2023

**Capital commitments**

The parent entity had no capital commitments as at 30 June 2024 and 30 June 2023.

**Significant accounting policies**

The accounting policies for the parent entity are consistent with those of the consolidated entity, as disclosed in Note 2.

## 26. INCOME TAX

The prima facie tax expense on pre-tax accounting loss from operations reconciles to the income tax expense as follows:

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Current tax expense	-	-
Deferred tax expense	-	-
Income tax expense	-	-
Accounting profit/(loss)	(12,491,037)	(7,497,092)
Tax at statutory rate of 25%	(3,122,759)	(1,874,273)
Non-deductible expenditure	970,956	397,070
Non-assessable income	(287,139)	(287,139)
Temporary timing difference and loss not recognised	1,793,553	1,173,445
Tax gains not brought to account as DTL	-	-
Refundable research expenditure	634,645	537,625
Income tax expense	-	-

### DEFERRED TAX ASSETS NOT BROUGHT TO ACCOUNT

Trade and other payables	10,964	11,357
Accruals	52,629	29,222
Employee benefits	60,348	38,173
Tax losses from previous periods	3,938,059	3,898,329
<b>Total deferred tax assets not brought to account</b>	<b>4,062,324</b>	<b>3,977,081</b>

### DEFERRED TAX LIABILITIES NOT BROUGHT TO ACCOUNT

NA	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

As at 30 June 2024, there was \$15,752,235 tax losses carried forward (2023: \$10,970,028).



## 27. LOSS PER SHARE

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Loss after income tax used in calculating basic and diluted earnings per share	(12,491,037)	(7,497,092)
	NO.	NO.
Weighted average number of ordinary shares used in calculating basic and diluted earnings per share	229,607,059	215,014,429
	CENTS	CENTS
Basic loss per share	(5.4)	(3.5)
Diluted loss per share	(5.4)	(3.5)

As the group incurred a loss for the period, the options on issue have an anti-dilutive effect, therefore the diluted EPS is equal to the basic eps. A total of 16,050,000 share options which could potentially dilute EPS in the future have been excluded from the dilute EPS calculation because they are anti-dilutive for the current period.

## 28. FINANCIAL INSTRUMENTS

### **Financial risk management objectives**

The Company's principal financial instruments comprise cash, receivables, payables and related party loans.

Primary responsibility for identification and control of financial risks rests with the Board. The Board reviews and agrees policies for managing each of the risks identified.

The Company manages its exposure to key financial risks, including interest rate, credit and liquidity risks in accordance with the Company's risk management policy. The primary objective of the policy is to reduce the volatility of cash flows and asset values arising from such movements.

The Company uses different methods to measure and manage the different types of risks to which it is exposed. These include monitoring the levels of exposure to interest rate risk, ageing analysis and monitoring of credit allowances to manage credit risk and the use of future cash flow forecasts to monitor liquidity risk.





## 28. FINANCIAL INSTRUMENTS (CONTINUED)

**Credit risk**

The carrying amount of the Company's financial assets represents the maximum credit exposure. The Company's maximum exposure to credit risk at the reporting date was:

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Cash and cash equivalents	3,554,485	5,164,663
Trade and other receivables	1,144,841	1,032,801
	<b>4,699,326</b>	<b>6,197,464</b>

The Company's maximum exposure to interest rates at the reporting date was:

			INTEREST RATE EXPOSURE			
	RANGE OF EFFECTIVE INTEREST RATE (%)	CARRYING AMOUNT \$	VARIABLE INTEREST RATE \$	NON INTEREST BEARING \$	FLOATING INTEREST RATE \$	TOTAL \$
2024 FINANCIAL ASSETS – CURRENT						
Cash and cash equivalents	0.36	3,554,485	3,554,485	–	–	3,554,485
2023 FINANCIAL ASSETS – CURRENT						
Cash and cash equivalents	0.36	5,164,663	5,164,663	–	–	5,164,663

The Company's maximum exposure to credit risk for trade and other receivables at the reporting date was:

		PAST DUE BUT NOT IMPAIRED				
	CARRYING AMOUNT \$	NOT PAST DUE AND NOT IMPAIRED \$	1-3 MONTHS \$	3 MONTHS- 1 YEAR \$	1-5 YEARS \$	IMPAIRED FINANCIAL ASSETS \$
<b>2024 FINANCIAL ASSETS - CURRENT</b>						
Cash and cash equivalents	3,554,485	3,554,485	3,554,485	-	-	-
Trade and other receivables	1,144,841	1,144,841	1,144,841	-	-	-
	<b>4,699,326</b>	<b>4,699,326</b>	<b>4,699,326</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>2023 FINANCIAL ASSETS - CURRENT</b>						
Cash and cash equivalents	5,164,663	5,164,663	5,164,663	-	-	-
Trade and other receivables	1,032,801	1,032,801	1,032,801	-	-	-
	<b>6,197,464</b>	<b>6,197,464</b>	<b>6,197,464</b>	<b>-</b>	<b>-</b>	<b>-</b>

## 28. FINANCIAL INSTRUMENTS (CONTINUED)

### Liquidity risk

The carrying amount of the Company's financial liabilities represents the maximum liquidity risk. The Company's maximum exposure to liquidity risk at the reporting date was:

	CONSOLIDATED 30 JUN 2024 \$	CONSOLIDATED 30 JUN 2023 \$
Trade and other payables	1,477,615	1,166,876

The following table discloses the contractual maturity analysis at the reporting date:

	CARRYING AMOUNT \$	LESS THAN 1 MONTH \$	1-3 MONTHS \$	3 MONTHS- 1 YEAR \$	1-5 YEARS \$	OVER 5 YEARS \$
<b>2024 FINANCIAL LIABILITIES</b>						
Trade and other payables	1,098,272	-	683,147	415,125	-	-
Lease liability	567,020	8,354	11,957	55,085	374,402	117,222
<b>2023 FINANCIAL LIABILITIES - CURRENT</b>						
Trade and other payables	866,876	-	-	300,000	-	-
Lease liability	172,219	10,561	21,121	95,045	45,492	-

### Market risk

The Company is not materially exposed to any foreign currency risk or other price risk at the report date. The Company's only exposure to interest rate risk is cash as disclosed below.

### Sensitivity disclosure analysis

Taking into account past performance, future expectations and economic forecasts, the Company believes the following movements are 'reasonably possible' over the next 12 months (base rates are sourced from the Reserve Bank of Australia).

It is considered that 50 basis points is a 'reasonably possible' estimate of potential variations in the interest rate.

The following table discloses the impact on net operating result and equity for each category of financial instrument held by the Company at year end as presented to key management personnel, if changes in the relevant risk occur.

	CARRYING AMOUNT \$	INTEREST RATE RISK			
		+0.5%		-0.5%	
		PROFIT \$	EQUITY \$	PROFIT \$	EQUITY \$
<b>2024 FINANCIAL ASSETS - CURRENT</b>					
Cash and cash equivalents	3,554,485	17,772	17,772	(17,772)	(17,772)
<b>2023 FINANCIAL ASSETS - CURRENT</b>					
Cash and cash equivalents	5,164,663	25,823	25,823	(25,823)	(25,823)

## 29. CASH FLOW INFORMATION

	30 JUN 2024 \$	30 JUN 2023 \$
<b>RECONCILIATION OF NETT PROFIT AFTER TAX TO NET CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Loss before income tax	(12,491,037)	(7,497,092)
<b>ADJUSTMENT FOR:</b>		
Effects of currency translation on cash	14,500	(108,010)
Depreciation of plant and equipment	243,296	140,991
Amortisation of intangible assets	386,894	202,980
Share based payments	3,843,240	1,562,838
<b>Operating loss before working capital</b>	<b>(8,003,107)</b>	<b>(5,698,293)</b>
<b>CHANGES IN WORKING CAPITAL:</b>		
Decrease/(Increase) in trade receivables	(136,006)	(66,963)
Decrease/(Increase) in other assets	(159,565)	(121,192)
(Decrease)/Increase in trade and other payables	305,444	525,103
(Decrease)/Increase in provisions	88,698	(92,533)
<b>Net cash (used in) operating activities</b>	<b>(7,904,536)</b>	<b>(5,453,878)</b>



## CONSOLIDATED ENTITY DISCLOSURE STATEMENT

The consolidated financial statements incorporate the assets, liabilities and results of the following wholly-owned subsidiaries in accordance with the accounting policy in Note 2.

NAME OF ENTITY	TYPE OF ENTITY	TRUSTEE PARTNER OR PARTICIPANT IN JOINT VENTURE	COUNTRY OF INCORPORATION	AUSTRALIAN RESIDENT OF FOREIGN ENTITY (FOR TAX PURPOSE)	FOREIGN TAX JURISDICTION FOR FOREIGN RESIDENTS	OWNERSHIP 30 JUNE 2024
ClearVue Technologies Limited	Body Corporate	NA	Australia	Australia	NA	NA
ClearVue International Pty Ltd	Body Corporate	NA	Australia	Australia	NA	100%
ClearVue USA Inc	Body Corporate	NA	United States of America	Foreign	United States of America	100%
ClearVue (Asia) Pte Ltd	Body Corporate	NA	Singapore	Foreign	Singapore	100%
ClearVue Europe BV	Body Corporate	NA	Netherlands	Foreign	Netherlands	100%
ClearVue Europe Holdings BV	Body Corporate	NA	Netherlands	Foreign	Netherlands	100%

### ***Basis of preparation***

The consolidated entity disclosure statement (CEDS) has been prepared in accordance with subsection 295(3A)(a) of the Corporations Act 2001. The entities listed in the statement are ClearVue Technologies Limited and all the entities it controls in accordance with AASB 10 Consolidated Financial Statements.



1. In the opinion of the Directors of ClearVue Technologies Limited:

- a) the consolidated financial report and notes are in accordance with the Corporations Act 2001, including:
  - i) giving a true and fair view of its financial position as at 30 June 2024 and of its performance for the period from 1 July 2023 to 30 June 2024; and
  - ii) complying with Australian Accounting Standards (including the Australian Interpretations) and the Corporations Regulations 2001; and
- b) the consolidated entity disclosure statement on page 63 is true and correct as at 30 June 2024; and
- c) at the date of this declaration, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

2. The financial report comply with International Financial Reporting Standards (IFRS) as described in Note 2.

The Directors have been given the declarations required by section 295A of the Corporations Act 2001.

The declaration is made in accordance with a resolution of the Board of Directors required by section 295(5)(a) of the Corporations Act 2001.



Victor Rosenberg

Perth WA

Date: 30 September 2024



**Grant Thornton Audit Pty Ltd**  
 Level 43 Central Park  
 152-158 St Georges Terrace  
 Perth WA 6000  
 PO Box 7757  
 Cloisters Square  
 Perth WA 6850  
 T +61 8 9480 2000

## Independent Auditor's Report

### To the Members of ClearVue Technologies Limited

#### Report on the audit of the financial report

##### Opinion

We have audited the financial report of ClearVue Technologies Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2024, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the *Corporations Act 2001*, including:

- a giving a true and fair view of the Group's financial position as at 30 June 2024 and of its performance for the year ended on that date; and
- b complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

##### Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

##### Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

**www.grantthornton.com.au**  
**ACN-130 913 594**

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389. 'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards Legislation.

Key audit matter	How our audit addressed the key audit matter
<b>Capitalised intangible assets – Note 8</b>	
<p>Intangible assets comprise patents and trademarks of \$3,378,822 and a development asset of \$2,588,727.</p> <p>During the year, the Group capitalised \$830,470 in relation to patents and trademarks and \$408,877 in relation to the development asset.</p> <p>Patents and trademarks and the development asset are being amortised over the useful life of 20 years. An amortisation expense of \$247,520 (Patents and Trademarks) and \$139,379 (Development Asset) has been included in the statement of profit or loss and other comprehensive income.</p> <p>AASB 138 <i>Intangible Assets</i> sets out the specific requirements to be met to capitalise costs. Intangible assets should be amortised over their useful economic lives in accordance with AASB 138.</p> <p>This area is a key audit matter due to subjectivity and management judgement in assessing whether costs meet the development phase criteria described in AASB 138</p>	<p>Our procedures included, amongst others:</p> <ul style="list-style-type: none"> <li>assessing the Group's accounting policy for compliance with AASB 138;</li> <li>evaluating management's assessment of each project for compliance with the recognition criteria set out in AASB 138; including discussing project plans with management to develop an understanding of nature and feasibility of key projects;</li> <li>testing a sample of costs capitalised by tracing to underlying support, including timesheets, employment contracts and invoices from suppliers and assessing whether the expense was attributable to the development of the asset and accordance with the recognition criteria of AASB 138;</li> <li>assessing the reasonableness of the useful lives attributed to patents and trademarks and whether the amortisation expense was recorded based on the assigned useful lives; and</li> <li>assessing the appropriateness of related disclosures in the financial statements.</li> </ul>
<b>Research and development tax incentives – Note 4 and Note 15</b>	
<p>Under the research and development (R&amp;D) tax incentive scheme, the Group receives a 43.5% refundable tax offset (2023: 43.5%) of eligible expenditure if the entity is a base rate entity for an income year if;</p> <ul style="list-style-type: none"> <li>The company's aggregate turnover for that income year is less than the aggregate turnover threshold for that income year \$50 million, and</li> <li>it has 80% or less of their assessable income in that income year is base rate entity passive income.</li> </ul> <p>An R&amp;D plan is filed with AusIndustry in the following financial year and based on this filing, the Group receives the incentive in cash. Management performs a detailed review of the Group's total R&amp;D expenditure to estimate the refundable tax offset receivable under the R&amp;D tax incentive legislation.</p> <p>This is a key audit matter due to the material amount of the accrual and the degree of judgement and interpretation of the R&amp;D tax legislation required by management to assess the eligibility of the R&amp;D expenditure under the scheme.</p>	<p>Our procedures included, amongst others:</p> <ul style="list-style-type: none"> <li>obtaining, through discussions with management, an understanding of the process to estimate the claim;</li> <li>utilising an internal R&amp;D tax specialist to; <ul style="list-style-type: none"> <li>assist in reviewing the expenditure methodology employed by management for consistency with the R&amp;D tax offset rules; and</li> <li>considering the nature of the expenses against the eligibility criteria of the R&amp;D tax incentive scheme to form a view about whether the expenses included in the estimate meet the eligibility criteria;</li> </ul> </li> <li>comparing the nature of the R&amp;D expenditure included in the current year estimate to the prior year's claim;</li> <li>selecting a sample of R&amp;D expenditure and agreed to supporting documentation to ensure appropriate classification, the validity of the claimed amount, and eligibility against the R&amp;D tax incentive scheme criteria; and</li> <li>assessing the appropriateness of financial statement disclosures.</li> </ul>

Grant Thornton Audit Pty Ltd

## Information other than the financial report and auditor's report thereon

The Directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the year ended 30 June 2024, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## Responsibilities of the Directors for the financial report

The Directors of the Company are responsible for the preparation of:

- a) the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 (other than the consolidated entity disclosure statement); and
- b) the consolidated entity disclosure statement that is true and correct in accordance with the Corporations Act 2001, and

for such internal control as the directors determine is necessary to enable the preparation of:

- i) the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- ii) the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the Directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

## Auditor's responsibilities for the audit of the financial report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at: [http://www.auasb.gov.au/auditors\\_responsibilities/ar1\\_2020.pdf](http://www.auasb.gov.au/auditors_responsibilities/ar1_2020.pdf). This description forms part of our auditor's report.

## Report on the remuneration report

### Opinion on the remuneration report

We have audited the Remuneration Report included in pages 15 to 27 of the Directors' report for the year ended 30 June 2024.

In our opinion, the Remuneration Report of ClearVue Technologies Limited, for the year ended 30 June 2024 complies with section 300A of the *Corporations Act 2001*.



**Responsibilities**

The Directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

Grant Thornton

GRANT THORNTON AUDIT PTY LTD  
Chartered Accountants



J C Rubelli  
Partner – Audit & Assurance  
Perth, 30 September 2024

---

Grant Thornton Audit Pty Ltd

## ASX ADDITIONAL INFORMATION

Additional information required by the ASX Limited Listing Rules not disclosed elsewhere in this Annual Report is set out below.

### SHAREHOLDINGS

The issued capital of the Company at 27 September 2024 is 243,283,474 ordinary fully paid shares.

SHARES RANGE	NO. OF HOLDERS	NO. OF SHARES
1 - 1,000	479	328,413
1,001 - 5,000	2,089	5,593,387
5,001 - 10,000	884	6,990,201
10,001 - 100,000	1,533	50,904,220
Over 100,000	299	179,467,253
	<b>5,284</b>	<b>243,283,474</b>

662 shareholders holding less than a marketable parcel

SHAREHOLDERS BY LOCATION	NO. OF HOLDERS	NO. OF SHARES
Australian holders	5,199	234,810,568
Overseas holders	85	8,472,906
	<b>5,284</b>	<b>243,283,474</b>

TOP 20 SHAREHOLDERS OF QUOTED SHARES AS AT 27 SEPTEMBER 2024		NO. OF SHARES HELD	% HELD
1	Luminate Pty Ltd	20,387,186	8.38%
2	I Rosenberg	10,358,057	4.26%
3	Ian Rosenberg	9,959,206	4.09%
4	HAWERA PTY LTD <THE BAILEY FAMILY A/C>	7,170,000	2.95%
5	ELEVATION VENTURES PTY LTD <J3 A/C>	7,050,000	2.90%
6	Victor Rosenberg	6,293,012	2.59%
7	CITICORP NOMINEES PTY LIMITED	4,736,335	1.95%
8	MR STEVEN PANOMARENKO	3,709,109	1.52%
9	MRS THERESA ANNE SMITS	3,000,000	1.23%
10	BNP PARIBAS NOMINEES PTY LTD <CLEARSTREAM>	2,527,215	1.04%
11	ELEVATION VENTURES PTY LTD <LYFORD SAMARAS SUPER A/C>	2,426,618	1.00%
12	CUSTODIAL SERVICES LIMITED <BENEFICIARIES HOLDING A/C>	2,419,000	0.99%
13	MRS THERESA ANNE SMITS & MR BERT JOSEPH SMITS <SCIS SF A/C>	2,250,000	0.92%
14	DAVID & RESMIE GREER PTY LTD <D & R GREER SUPER FUND A/C>	2,237,790	0.92%
15	MR MARTIN GEORG DEIL	2,084,000	0.86%
16	MR RODNEY JAMES WELLSTEAD	1,800,000	0.74%
16	HOLDSWORTH BROS PTY LTD <HOLDSWORTH BROS S/F A/C>	1,800,000	0.74%
17	KELVERLEY PTY LTD <RERANI SUPER FUND A/C>	1,750,000	0.72%
18	BNP PARIBAS NOMS PTY LTD	1,720,322	0.71%
19	DENGOLD HOLDINGS PTY LTD <PANOMARENKO FAMILY A/C>	1,446,745	0.59%
20	MRS LUCIA SPASOJEVIC	1,410,000	0.58%
		<b>96,534,595</b>	<b>39.68%</b>

SUBSTANTIAL SHAREHOLDERS AS AT 27 SEPTEMBER 2024	NO. OF SHARES HELD	% HELD
Luminate Pty Ltd	20,387,186	8.38%

### Voting Rights

The holders of ordinary shares are entitled to one vote per share at meetings of the Group.

### OPTION HOLDINGS

CLASS	TERMS	NO. OF OPTIONS
A	Exercisable at \$0.40 each, expiring 30 November 2025	2,500,000
B	Exercisable at \$0.30 each, expiring 30 November 2024	2,625,000
C	Exercisable at \$0.50 each, expiring 30 November 2026	3,000,000
D	Exercisable at \$0.2475 each, expiring 12 July 2027	3,000,000
E	Exercisable at \$0 each, expiring 30 October 2027	500,000
F	Exercisable at \$0.50 each, expiring 13 December 2026	2,000,000
G	Exercisable at \$1.00 each, expiring 13 December 2026	2,000,000
H	Exercisable at \$0.75 each, expiring 12 March 2026	5,508,929
I	Exercisable at \$0.75 each, expiring 19 June 2026	93,333
J	Exercisable at \$0.549 each, expiring 30 June 2027	1,150,000
		<b>22,377,262</b>

### Unlisted Options (Class A-J)

OPTIONS RANGE	NO. OF HOLDERS	NO. OF SHARES
1 – 1,000	-	-
1,001 – 5,000	132	324,624
5,001 – 10,000	72	570,319
10,001 – 100,000	82	1,973,987
100,001 and over	24	19,508,332
	<b>310</b>	<b>22,377,262</b>

No holders hold more than 20% of the Company's Unlisted Options on issue.

### Voting Rights

Options have no voting rights.

## PERFORMANCE RIGHTS

CLASS	TERMS	NO. OF PERFORMANCE SHARES
A	Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s*	1,000,000
B	Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s*	3,000,000
C	Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s*	6,000,000
D	Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s*	1,000,000
E	Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s*	500,000
F	Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s*	500,000
G	Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s*	1,000,000
H	Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s*	500,000
I	Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s*	500,000
J	Converting 1:1 into fully paid ordinary shares on satisfaction of milestone/s*	1,000,000
		<b>15,000,000</b>

\*The Performance Rights in the relevant class will convert into Shares upon satisfaction of the milestones as follows:

**Class A Performance Rights:**

- In the event that the aggregate of the value of the ClearVue (Orders and the ClearVue Payments is equal to or greater than \$2,000,000 within a period of 24 months commencing on the date of issue of the Performance Rights (Issue Date) (Class A Milestone 1), each Class A Performance Right will vest and be convertible into one Share; or
- in the event that Class A Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$7,000,000 within a period of 36 months from the Issue Date (Class A Milestone 2), each Class A Performance Right will vest and be convertible into one Share; or
- in the event that neither Class A Milestone 1 or Class A Milestone 2 is satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Issue Date, each Class A Performance Right will vest and be convertible into one Share.

**Class B Performance Rights:**

- In the event that the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$5,000,000 within a period of 24 to 36 months from the Issue Date (Class B Milestone 1), each Class B Performance Right will vest and be convertible into one Share; or
- in the event that Class B Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$7,000,000 within a period of 36 months from the Issue Date (Class B Milestone 2), each Class B Performance Right will vest and be convertible into one Share; or
- in the event that neither Class B Milestone 1 or Class B Milestone 2 is satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Issue Date, each Class B Performance Right will vest and be convertible into one Share.

**Class C Performance Rights:**

- In the event that the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$10,000,000 within a period of 36 to 48 months from the Issue Date (Class C Milestone 1), each Class C Performance Right will vest and be convertible into one Share; or
- In the event that Class C Milestone 1 is not satisfied but the aggregate of the value of the ClearVue Orders and the ClearVue Payments is equal to or greater than \$17,000,000 within a period of 48 months from the Issue Date, each Class C Performance Right will vest and be convertible into one Share.

#### **Class D Performance Rights:**

In the event that the participant assisting the company completes the development and testing of vision and spandrel glass to achieve an A2 SO D1 fire rating confirmed by an independent third party testing, with such testing party approved by the company and certified to the EN13501.1 standard before the expiry date, each class D performance right will vest and be convertible into a share.

#### **Class E Performance Rights:**

In the event that the participant introduces an equity investor to the company where the equity investment transaction is concluded and / or the participant has carriage of concluding an equity investment transaction before the expiry date, each of the class E performance rights will vest and be convertible into a share.

#### **Class F Performance Rights:**

In the event that the participant introduces an equity investor to the company where the equity investment transaction is concluded and / or the participant has carriage of concluding an equity investment transaction before the expiry date, each of the class E performance rights will vest and be convertible into a share.

#### **Class G Performance Rights:**

In the event that the participant assists the company to complete an up-listing of its OTCQB US or ASX listing into the main US board of the NASDAQ or the NYSE before the expiry date or have commenced at least 3 months before the expiry date and such up-listing is completed within a further 6 months after the end of the expiry date, each of the class G performance rights will vest and be convertible into a share.

#### **Class H Performance Rights:**

In the event the share price for the ordinary shares of the company reaches \$0.50 and maintains a volume weighted average of \$0.50 per ordinary share for at least 14 days with and before the expiry date, each of the class H performance rights will vest and be convertible into a share.

#### **Class I Performance Rights:**

In the event that the company receives revenue of AUD\$1,500,000 from the sale of its own products (incorporating the ClearVue technology) during a twelve month period before the expiry date, each of the class E performance rights will vest and be convertible into a share.

#### **Class J Performance Rights:**

In the event that the company receives revenue of AUD\$1,500,000 from the sale of its own products (incorporating the ClearVue technology) during a twelve month period before the expiry date, each of the class E performance rights will vest and be convertible into a share.

#### **Performance Rights (Class A-J)**

PERFORMANCE RIGHTS RANGE	NO. OF HOLDERS	NO. OF RIGHTS
1 – 1,000	–	–
1,001 – 5,000	–	–
5,001 – 10,000	–	–
10,001 – 100,000	–	–
100,001 and over	4	15,000,000
	4	15,000,000

#### **Voting Rights**

Performance rights have no voting rights.



### RESTRICTED SECURITIES

There are no restricted securities on issue as at 27 September 2024.

### REQUIREMENT LISTING RULE 4.10.18

In accordance with the listing rule 4.10.18 the Company confirms that it is not currently subject to an on-market buyback.

### CORPORATE GOVERNANCE

The Company's corporate governance statement is found on the Company's website at [clearvuepv.com/investors/governance](https://clearvuepv.com/investors/governance)





ClearVue<sup>PV</sup>

**HEAD OFFICE & SHOWROOM**

📍 Suite 9 / 567 Newcastle Street  
West Perth, Western Australia 6005

☎ +61 8 9220 9020

✉ [hello@clearvuepv.com](mailto:hello@clearvuepv.com)

🌐 [www.clearvuepv.com](http://www.clearvuepv.com)

**US OFFICE**

📍 #712 1625 The Alameda  
San Jose CA 95126

☎ +1 408.352.5326

**INTERNATIONAL**

Amsterdam, Netherlands  
London, UK  
Singapore, Singapore